Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,23831756,THC ratios,"During ad libitum smoking, OF/P THC ratios were high (median, 6.1; range, 0.2-348.5) within 1 h after last smoking, decreasing to 0.1-20.7 (median, 2.1) by 13.0-17.1 h.",Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23831756/),,6.1,2323,DB00470,Dronabinol
,23831756,THC ratios,"During ad libitum smoking, OF/P THC ratios were high (median, 6.1; range, 0.2-348.5) within 1 h after last smoking, decreasing to 0.1-20.7 (median, 2.1) by 13.0-17.1 h.",Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23831756/),,2.1,2324,DB00470,Dronabinol
,23831756,THC ratios,"OF/P THC ratios also decreased during 5-days oral THC dosing, and after the smoked cannabis challenge, median OF/P THC ratios decreased from 1.4 to 5.5 (0.04-245.6) at 0.25 h to 0.12 to 0.17 (0.04-5.1) at 10.5 h post-smoking.",Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23831756/),,1.4,2325,DB00470,Dronabinol
,23831756,THC ratios,"OF/P THC ratios also decreased during 5-days oral THC dosing, and after the smoked cannabis challenge, median OF/P THC ratios decreased from 1.4 to 5.5 (0.04-245.6) at 0.25 h to 0.12 to 0.17 (0.04-5.1) at 10.5 h post-smoking.",Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23831756/),,5.5,2326,DB00470,Dronabinol
,23831756,THC ratios,"OF/P THC ratios also decreased during 5-days oral THC dosing, and after the smoked cannabis challenge, median OF/P THC ratios decreased from 1.4 to 5.5 (0.04-245.6) at 0.25 h to 0.12 to 0.17 (0.04-5.1) at 10.5 h post-smoking.",Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23831756/),,0.12,2327,DB00470,Dronabinol
,23831756,THC ratios,"OF/P THC ratios also decreased during 5-days oral THC dosing, and after the smoked cannabis challenge, median OF/P THC ratios decreased from 1.4 to 5.5 (0.04-245.6) at 0.25 h to 0.12 to 0.17 (0.04-5.1) at 10.5 h post-smoking.",Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23831756/),,0.17,2328,DB00470,Dronabinol
,28188235,Cmax,"OF THC maximum concentrations (Cmax) were similar in frequent as compared to occasional smokers, while blood THC Cmax were higher in frequent [mean (range) 17.7 (8.0-36.1) μg/L] smokers compared to occasional [8.2 (3.2-14.3) μg/L] smokers.",Cannabis Edibles: Blood and Oral Fluid Cannabinoid Pharmacokinetics and Evaluation of Oral Fluid Screening Devices for Predicting Δ9-Tetrahydrocannabinol in Blood and Oral Fluid following Cannabis Brownie Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28188235/),[μg] / [l],17.7,2472,DB00470,Dronabinol
,28188235,Cmax,"OF THC maximum concentrations (Cmax) were similar in frequent as compared to occasional smokers, while blood THC Cmax were higher in frequent [mean (range) 17.7 (8.0-36.1) μg/L] smokers compared to occasional [8.2 (3.2-14.3) μg/L] smokers.",Cannabis Edibles: Blood and Oral Fluid Cannabinoid Pharmacokinetics and Evaluation of Oral Fluid Screening Devices for Predicting Δ9-Tetrahydrocannabinol in Blood and Oral Fluid following Cannabis Brownie Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28188235/),[μg] / [l],8.2,2473,DB00470,Dronabinol
,18695931,maximal concentrations (Cmax),"Mean maximal concentrations (Cmax) were 135.1, 202.9 and 231.0 microg/L for THC and 9.2, 16.4 and 15.8 microg/L for 11-OH-THC after smoking a 29.3-, 49.1- and 69.4-mg THC cigarette, respectively.",Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18695931/),[μg] / [l],135.1,5235,DB00470,Dronabinol
,18695931,maximal concentrations (Cmax),"Mean maximal concentrations (Cmax) were 135.1, 202.9 and 231.0 microg/L for THC and 9.2, 16.4 and 15.8 microg/L for 11-OH-THC after smoking a 29.3-, 49.1- and 69.4-mg THC cigarette, respectively.",Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18695931/),[μg] / [l],202.9,5236,DB00470,Dronabinol
,18695931,maximal concentrations (Cmax),"Mean maximal concentrations (Cmax) were 135.1, 202.9 and 231.0 microg/L for THC and 9.2, 16.4 and 15.8 microg/L for 11-OH-THC after smoking a 29.3-, 49.1- and 69.4-mg THC cigarette, respectively.",Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18695931/),[μg] / [l],231.0,5237,DB00470,Dronabinol
,18695931,maximal concentrations (Cmax),"Mean maximal concentrations (Cmax) were 135.1, 202.9 and 231.0 microg/L for THC and 9.2, 16.4 and 15.8 microg/L for 11-OH-THC after smoking a 29.3-, 49.1- and 69.4-mg THC cigarette, respectively.",Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18695931/),[μg] / [l],9.2,5238,DB00470,Dronabinol
,18695931,maximal concentrations (Cmax),"Mean maximal concentrations (Cmax) were 135.1, 202.9 and 231.0 microg/L for THC and 9.2, 16.4 and 15.8 microg/L for 11-OH-THC after smoking a 29.3-, 49.1- and 69.4-mg THC cigarette, respectively.",Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18695931/),[μg] / [l],16.4,5239,DB00470,Dronabinol
,18695931,maximal concentrations (Cmax),"Mean maximal concentrations (Cmax) were 135.1, 202.9 and 231.0 microg/L for THC and 9.2, 16.4 and 15.8 microg/L for 11-OH-THC after smoking a 29.3-, 49.1- and 69.4-mg THC cigarette, respectively.",Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18695931/),[μg] / [l],15.8,5240,DB00470,Dronabinol
,2550702,urinary excretion half-life,"The urinary excretion half-life, calculated from the concentrations of delta 1-THC-7-oic acid versus time, ranged from 0.8-9.8 days with a mean (+/- SD) of 3.0 +/- 2.3 days.",Urinary excretion half-life of delta 1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550702/),d,0.8-9.8,8128,DB00470,Dronabinol
,2550702,urinary excretion half-life,"The urinary excretion half-life, calculated from the concentrations of delta 1-THC-7-oic acid versus time, ranged from 0.8-9.8 days with a mean (+/- SD) of 3.0 +/- 2.3 days.",Urinary excretion half-life of delta 1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550702/),d,3.0,8129,DB00470,Dronabinol
,6271847,half-life,CTX half-life was not significantly changed with use of THC (7.7 +/- 3.6 hours without versus 5.25 +/- 2.6 hours with THC).,Initial observations on the effects of delta 9-tetrahydrocannabinol on the plasma pharmacokinetics of cyclophosphamide and doxorubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6271847/),h,7.7,12331,DB00470,Dronabinol
,6271847,half-life,CTX half-life was not significantly changed with use of THC (7.7 +/- 3.6 hours without versus 5.25 +/- 2.6 hours with THC).,Initial observations on the effects of delta 9-tetrahydrocannabinol on the plasma pharmacokinetics of cyclophosphamide and doxorubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6271847/),h,5.25,12332,DB00470,Dronabinol
,6271847,half-life,"ADR half-life with THC was greater than without THC (175 +/- 197 hours versus 92 +/- 92 hours, respectively).",Initial observations on the effects of delta 9-tetrahydrocannabinol on the plasma pharmacokinetics of cyclophosphamide and doxorubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6271847/),h,175,12333,DB00470,Dronabinol
,6271847,half-life,"ADR half-life with THC was greater than without THC (175 +/- 197 hours versus 92 +/- 92 hours, respectively).",Initial observations on the effects of delta 9-tetrahydrocannabinol on the plasma pharmacokinetics of cyclophosphamide and doxorubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6271847/),h,92,12334,DB00470,Dronabinol
,6271847,areas under the curves,Total drug exposure as determined by areas under the curves were similar (12.4 +/- 6 microM . hr without versus 13.8 +/- 4 microM . hr with THC).,Initial observations on the effects of delta 9-tetrahydrocannabinol on the plasma pharmacokinetics of cyclophosphamide and doxorubicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6271847/),h·μM,12.4,12335,DB00470,Dronabinol
,6271847,areas under the curves,Total drug exposure as determined by areas under the curves were similar (12.4 +/- 6 microM . hr without versus 13.8 +/- 4 microM . hr with THC).,Initial observations on the effects of delta 9-tetrahydrocannabinol on the plasma pharmacokinetics of cyclophosphamide and doxorubicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6271847/),h·μM,13.8,12336,DB00470,Dronabinol
,29287930,relative bioavailability,"Their relative bioavailability was also higher (131% and 116% for CBD and THC, respectively).","PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29287930/),%,131,14217,DB00470,Dronabinol
,29287930,relative bioavailability,"Their relative bioavailability was also higher (131% and 116% for CBD and THC, respectively).","PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29287930/),%,116,14218,DB00470,Dronabinol
,29287930,Tmax,Values of Tmax were significantly shorter for both CBD and THC (median of 1.3 h for PTL401 vs. 3.5 h for the spray).,"PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29287930/),h,1.3,14219,DB00470,Dronabinol
,29287930,Tmax,Values of Tmax were significantly shorter for both CBD and THC (median of 1.3 h for PTL401 vs. 3.5 h for the spray).,"PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29287930/),h,3.5,14220,DB00470,Dronabinol
,9071430,Cmax,"Pharmacokinetic parameters measured after 2 weeks of therapy for M750 were Cmax = 985 ng/ml and AUC = 22,487 ng x hr/ml, and for dronabinol and its active metabolite (HO-THC), respectively, were Cmax = 2.01; 4.61 ng/ml and AUC = 5.3; 23.7 ng x hr/ml.",The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9071430/),[ng] / [ml],985,14323,DB00470,Dronabinol
,9071430,AUC,"Pharmacokinetic parameters measured after 2 weeks of therapy for M750 were Cmax = 985 ng/ml and AUC = 22,487 ng x hr/ml, and for dronabinol and its active metabolite (HO-THC), respectively, were Cmax = 2.01; 4.61 ng/ml and AUC = 5.3; 23.7 ng x hr/ml.",The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9071430/),[h·ng] / [ml],"22,487",14324,DB00470,Dronabinol
,9071430,Cmax,"Pharmacokinetic parameters measured after 2 weeks of therapy for M750 were Cmax = 985 ng/ml and AUC = 22,487 ng x hr/ml, and for dronabinol and its active metabolite (HO-THC), respectively, were Cmax = 2.01; 4.61 ng/ml and AUC = 5.3; 23.7 ng x hr/ml.",The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9071430/),[ng] / [ml],2.01,14325,DB00470,Dronabinol
,9071430,Cmax,"Pharmacokinetic parameters measured after 2 weeks of therapy for M750 were Cmax = 985 ng/ml and AUC = 22,487 ng x hr/ml, and for dronabinol and its active metabolite (HO-THC), respectively, were Cmax = 2.01; 4.61 ng/ml and AUC = 5.3; 23.7 ng x hr/ml.",The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9071430/),[ng] / [ml],4.61,14326,DB00470,Dronabinol
,9071430,AUC,"Pharmacokinetic parameters measured after 2 weeks of therapy for M750 were Cmax = 985 ng/ml and AUC = 22,487 ng x hr/ml, and for dronabinol and its active metabolite (HO-THC), respectively, were Cmax = 2.01; 4.61 ng/ml and AUC = 5.3; 23.7 ng x hr/ml.",The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9071430/),[h·ng] / [ml],5.3,14327,DB00470,Dronabinol
,9071430,AUC,"Pharmacokinetic parameters measured after 2 weeks of therapy for M750 were Cmax = 985 ng/ml and AUC = 22,487 ng x hr/ml, and for dronabinol and its active metabolite (HO-THC), respectively, were Cmax = 2.01; 4.61 ng/ml and AUC = 5.3; 23.7 ng x hr/ml.",The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9071430/),[h·ng] / [ml],23.7,14328,DB00470,Dronabinol
,7938127,latency to,"The duration of all marihuana- and cocaine-related positive subjective effects was unchanged when both drugs were given, but marihuana pretreatment significantly reduced the latency to cocaine effects, from 1.87 to 0.53 min, and decreased the duration of dysphoric or bad effects, from 2.1 to 0.5 min.",Marihuana smoking increases plasma cocaine levels and subjective reports of euphoria in male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7938127/),min,1.87,16304,DB00470,Dronabinol
,7938127,latency to,"The duration of all marihuana- and cocaine-related positive subjective effects was unchanged when both drugs were given, but marihuana pretreatment significantly reduced the latency to cocaine effects, from 1.87 to 0.53 min, and decreased the duration of dysphoric or bad effects, from 2.1 to 0.5 min.",Marihuana smoking increases plasma cocaine levels and subjective reports of euphoria in male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7938127/),min,0.53,16305,DB00470,Dronabinol
,7938127,Peak plasma cocaine levels,"Peak plasma cocaine levels were 122.8 +/- 26.6 ng/ml after placebo marihuana, but pretreatment with the high-dose marihuana resulted in a significant increase in peak cocaine levels (233.8 +/- 19.2 ng/ml) and the apparent bioavailability as determined by area under the curve (AUC) analysis.",Marihuana smoking increases plasma cocaine levels and subjective reports of euphoria in male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7938127/),[ng] / [ml],122.8,16306,DB00470,Dronabinol
,7938127,peak cocaine levels,"Peak plasma cocaine levels were 122.8 +/- 26.6 ng/ml after placebo marihuana, but pretreatment with the high-dose marihuana resulted in a significant increase in peak cocaine levels (233.8 +/- 19.2 ng/ml) and the apparent bioavailability as determined by area under the curve (AUC) analysis.",Marihuana smoking increases plasma cocaine levels and subjective reports of euphoria in male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7938127/),[ng] / [ml],233.8,16307,DB00470,Dronabinol
,26019183,maximum blood concentrations (Cmax),"Median (range) maximum blood concentrations (Cmax) for low and high THC doses (no alcohol) were 32.7 (11.4-66.2) and 42.2 (15.2-137) μg/L THC, respectively, and 2.8 (0-9.1) and 5.0 (0-14.2) μg/L 11-OH-THC.",Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26019183/),[μg] / [l],32.7,30659,DB00470,Dronabinol
,26019183,maximum blood concentrations (Cmax),"Median (range) maximum blood concentrations (Cmax) for low and high THC doses (no alcohol) were 32.7 (11.4-66.2) and 42.2 (15.2-137) μg/L THC, respectively, and 2.8 (0-9.1) and 5.0 (0-14.2) μg/L 11-OH-THC.",Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26019183/),[μg] / [l],42.2,30660,DB00470,Dronabinol
,26019183,maximum blood concentrations (Cmax),"Median (range) maximum blood concentrations (Cmax) for low and high THC doses (no alcohol) were 32.7 (11.4-66.2) and 42.2 (15.2-137) μg/L THC, respectively, and 2.8 (0-9.1) and 5.0 (0-14.2) μg/L 11-OH-THC.",Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26019183/),[μg] / [l],2.8,30661,DB00470,Dronabinol
,26019183,maximum blood concentrations (Cmax),"Median (range) maximum blood concentrations (Cmax) for low and high THC doses (no alcohol) were 32.7 (11.4-66.2) and 42.2 (15.2-137) μg/L THC, respectively, and 2.8 (0-9.1) and 5.0 (0-14.2) μg/L 11-OH-THC.",Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26019183/),[μg] / [l],5.0,30662,DB00470,Dronabinol
,26019183,Cmax,"With alcohol, low and high dose Cmax values were 35.3 (13.0-71.4) and 67.5 (18.1-210) μg/L THC and 3.7 (1.4-6.0) and 6.0 (0-23.3) μg/L 11-OH-THC, significantly higher than without alcohol.",Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26019183/),[μg] / [l],35.3,30663,DB00470,Dronabinol
,26019183,Cmax,"With alcohol, low and high dose Cmax values were 35.3 (13.0-71.4) and 67.5 (18.1-210) μg/L THC and 3.7 (1.4-6.0) and 6.0 (0-23.3) μg/L 11-OH-THC, significantly higher than without alcohol.",Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26019183/),[μg] / [l],67.5,30664,DB00470,Dronabinol
,26019183,Cmax,"With alcohol, low and high dose Cmax values were 35.3 (13.0-71.4) and 67.5 (18.1-210) μg/L THC and 3.7 (1.4-6.0) and 6.0 (0-23.3) μg/L 11-OH-THC, significantly higher than without alcohol.",Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26019183/),[μg] / [l],3.7,30665,DB00470,Dronabinol
,26019183,Cmax,"With alcohol, low and high dose Cmax values were 35.3 (13.0-71.4) and 67.5 (18.1-210) μg/L THC and 3.7 (1.4-6.0) and 6.0 (0-23.3) μg/L 11-OH-THC, significantly higher than without alcohol.",Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26019183/),[μg] / [l],6.0,30666,DB00470,Dronabinol
,32445190,plasma Cmax,"Following inhalation of 0.5 mg or 1mg, Δ9 -THC plasma Cmax ± SD were 14.3 ± 7.7 and 33.8 ± 25.7 ng/ml.","The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32445190/),[ng] / [ml],14.3,30681,DB00470,Dronabinol
,32445190,plasma Cmax,"Following inhalation of 0.5 mg or 1mg, Δ9 -THC plasma Cmax ± SD were 14.3 ± 7.7 and 33.8 ± 25.7 ng/ml.","The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32445190/),[ng] / [ml],33.8,30682,DB00470,Dronabinol
,32445190,Tmax,"Tmax ± SD were 3.7 ± 1.4 and 4.4 ± 2.1 min, and AUC0 → infinity ±SD were 300 ± 144 and 769 ± 331 ng*min/ml, respectively.","The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32445190/),min,3.7,30683,DB00470,Dronabinol
,32445190,Tmax,"Tmax ± SD were 3.7 ± 1.4 and 4.4 ± 2.1 min, and AUC0 → infinity ±SD were 300 ± 144 and 769 ± 331 ng*min/ml, respectively.","The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32445190/),min,4.4,30684,DB00470,Dronabinol
,32445190,AUC0 → infinity,"Tmax ± SD were 3.7 ± 1.4 and 4.4 ± 2.1 min, and AUC0 → infinity ±SD were 300 ± 144 and 769 ± 331 ng*min/ml, respectively.","The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32445190/),[min·ng] / [ml],300,30685,DB00470,Dronabinol
,32445190,AUC0 → infinity,"Tmax ± SD were 3.7 ± 1.4 and 4.4 ± 2.1 min, and AUC0 → infinity ±SD were 300 ± 144 and 769 ± 331 ng*min/ml, respectively.","The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32445190/),[min·ng] / [ml],769,30686,DB00470,Dronabinol
,10564064,peak concentrations,Distribution studies indicated that peak concentrations of drug both in blood (30 microg/mL) and brain (2 microg/mL) were rapidly (5 min) achieved after iv administration of a selected prodrug to rats.,In vitro and in vivo study of water-soluble prodrugs of dexanabinol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10564064/),[μg] / [ml],30,31489,DB00470,Dronabinol
,10564064,peak concentrations,Distribution studies indicated that peak concentrations of drug both in blood (30 microg/mL) and brain (2 microg/mL) were rapidly (5 min) achieved after iv administration of a selected prodrug to rats.,In vitro and in vivo study of water-soluble prodrugs of dexanabinol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10564064/),[μg] / [ml],2,31490,DB00470,Dronabinol
,31747464,steady-state volume of distribution (VdSS ),A 3-compartment model of THC was developed that has a steady-state volume of distribution (VdSS ) of 3401 ± 788 L and a clearance of 0.72 ± 0.10 L/min.,Population pharmacokinetic modeling of plasma Δ9-tetrahydrocannabinol and an active and inactive metabolite following controlled smoked cannabis administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31747464/),l,3401,32492,DB00470,Dronabinol
,31747464,clearance,A 3-compartment model of THC was developed that has a steady-state volume of distribution (VdSS ) of 3401 ± 788 L and a clearance of 0.72 ± 0.10 L/min.,Population pharmacokinetic modeling of plasma Δ9-tetrahydrocannabinol and an active and inactive metabolite following controlled smoked cannabis administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31747464/),[l] / [min],0.72,32493,DB00470,Dronabinol
,31747464,VdSS,11-OH-THC was characterized by 50 ± 6% of the THC being directly cleared to a 3-compartment model with a VdSS of 415.2 ± 4.3 L and clearance of 0.78 ± 0.05 L/min.,Population pharmacokinetic modeling of plasma Δ9-tetrahydrocannabinol and an active and inactive metabolite following controlled smoked cannabis administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31747464/),l,415.2,32494,DB00470,Dronabinol
,31747464,clearance,11-OH-THC was characterized by 50 ± 6% of the THC being directly cleared to a 3-compartment model with a VdSS of 415.2 ± 4.3 L and clearance of 0.78 ± 0.05 L/min.,Population pharmacokinetic modeling of plasma Δ9-tetrahydrocannabinol and an active and inactive metabolite following controlled smoked cannabis administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31747464/),[l] / [min],0.78,32495,DB00470,Dronabinol
,31747464,VdSS,The THCCOOH model shared the central compartment of the 11-OH-THC model with a VdSS of 29.1 ± 0.05 L and a clearance of 0.12 ± 0.02 L/min.,Population pharmacokinetic modeling of plasma Δ9-tetrahydrocannabinol and an active and inactive metabolite following controlled smoked cannabis administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31747464/),l,29.1,32496,DB00470,Dronabinol
,31747464,clearance,The THCCOOH model shared the central compartment of the 11-OH-THC model with a VdSS of 29.1 ± 0.05 L and a clearance of 0.12 ± 0.02 L/min.,Population pharmacokinetic modeling of plasma Δ9-tetrahydrocannabinol and an active and inactive metabolite following controlled smoked cannabis administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31747464/),[l] / [min],0.12,32497,DB00470,Dronabinol
,15107145,time of maximum excretion rate,"No significant differences (P </= 0.05) were observed in mean time of maximum excretion rate, mean maximum excretion rate, and mean terminal elimination half-life (t(1/2)) between the four THC doses, with ranges of 67.4 to 94.9 h, 0.9 to 16.3 micro g/h, and 44.2 to 64.0 h, respectively.",Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15107145/),h,67.4 to 94.9,33052,DB00470,Dronabinol
,15107145,maximum excretion rate,"No significant differences (P </= 0.05) were observed in mean time of maximum excretion rate, mean maximum excretion rate, and mean terminal elimination half-life (t(1/2)) between the four THC doses, with ranges of 67.4 to 94.9 h, 0.9 to 16.3 micro g/h, and 44.2 to 64.0 h, respectively.",Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15107145/),[μg] / [h],0.9 to 16.3,33053,DB00470,Dronabinol
,15107145,terminal elimination half-life (t(1/2)),"No significant differences (P </= 0.05) were observed in mean time of maximum excretion rate, mean maximum excretion rate, and mean terminal elimination half-life (t(1/2)) between the four THC doses, with ranges of 67.4 to 94.9 h, 0.9 to 16.3 micro g/h, and 44.2 to 64.0 h, respectively.",Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15107145/),h,44.2 to 64.0,33054,DB00470,Dronabinol
,15107145,apparent elimination t(1/2),"Mean apparent elimination t(1/2) of 24.1 +/- 7.8 and 21.1 +/- 4.3 h for the 7.5 and 14.8 mg/day doses, respectively, were calculated from the excretion rate curve prior to the last urine sample with a THCCOOH concentration >/= 15 ng/mL.",Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15107145/),h,24.1,33055,DB00470,Dronabinol
,15107145,apparent elimination t(1/2),"Mean apparent elimination t(1/2) of 24.1 +/- 7.8 and 21.1 +/- 4.3 h for the 7.5 and 14.8 mg/day doses, respectively, were calculated from the excretion rate curve prior to the last urine sample with a THCCOOH concentration >/= 15 ng/mL.",Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15107145/),h,21.1,33056,DB00470,Dronabinol
,15107145,terminal urinary elimination t(1/2),This study demonstrated that the terminal urinary elimination t(1/2) of THCCOOH following oral administration was approximately two to three days for doses ranging from 0.39 to 14.8 mg/d.,Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15107145/),d,two to three,33057,DB00470,Dronabinol
,20112012,times of the last detectable levels,"The times of the last detectable levels were 2-8, 6-96, and 48-120 h.",Plasma and urine profiles of Delta9-tetrahydrocannabinol and its metabolites 11-hydroxy-Delta9-tetrahydrocannabinol and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol after cannabis smoking by male volunteers to estimate recent consumption by athletes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20112012/),h,2-8,36853,DB00470,Dronabinol
,20112012,times of the last detectable levels,"The times of the last detectable levels were 2-8, 6-96, and 48-120 h.",Plasma and urine profiles of Delta9-tetrahydrocannabinol and its metabolites 11-hydroxy-Delta9-tetrahydrocannabinol and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol after cannabis smoking by male volunteers to estimate recent consumption by athletes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20112012/),h,6-96,36854,DB00470,Dronabinol
,20112012,times of the last detectable levels,"The times of the last detectable levels were 2-8, 6-96, and 48-120 h.",Plasma and urine profiles of Delta9-tetrahydrocannabinol and its metabolites 11-hydroxy-Delta9-tetrahydrocannabinol and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol after cannabis smoking by male volunteers to estimate recent consumption by athletes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20112012/),h,48-120,36855,DB00470,Dronabinol
,29125702,Tmax,Tmax following both modes of delivery was 3-3.5 hours postdosing.,Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29125702/),h,3-3.5,41358,DB00470,Dronabinol
,29125702,Bioavailability,Bioavailability of CBD in the 10-mg PTL101 dose was 134% relative to the reference spray.,Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29125702/),%,134,41359,DB00470,Dronabinol
,26257143,peak breath alcohol concentration [BrAC],"Healthy adult occasional-to-moderate cannabis smokers received a vaporized placebo or active cannabis (2.9% and 6.7% Δ(9) -tetrahydrocannabinol, THC) with or without oral low-dose alcohol (~0.065g/210L peak breath alcohol concentration [BrAC]) in a within-subjects design.","Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26257143/),,0.065,42234,DB00470,Dronabinol
,25752889,heart rate,"After the 0.75-mg dose, VAS internal perception (0.025 units; 95% CI 0.010-0.040) and heart rate (2 beats/min; 95% CI 0.4-3.8) increased significantly.","Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25752889/),[beats] / [min],2,43169,DB00470,Dronabinol
,25752889,Body sway-eyes-closed,Body sway-eyes-closed increased only after 1.5 mg (0.59°/s; 95% CI 0.13-1.06).,"Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25752889/),[°] / [s],0.59,43170,DB00470,Dronabinol
,25752889,T max,"The median T max was 1-2 h, with THC pharmacokinetics increasing linearly with increasing dose, with wide interindividual variability (CV% up to 140%).","Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25752889/),h,1-2,43171,DB00470,Dronabinol
,25752889,C max,The mean C max (ng/mL) after the first dose (0-6 h) was 0.41 (0.18-0.90) for the 0.75-mg dose and 1.01 (0.53-1.92) for the 1.5-mg dose.,"Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25752889/),[ng] / [ml],0.41,43172,DB00470,Dronabinol
,25752889,C max,The mean C max (ng/mL) after the first dose (0-6 h) was 0.41 (0.18-0.90) for the 0.75-mg dose and 1.01 (0.53-1.92) for the 1.5-mg dose.,"Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25752889/),[ng] / [ml],1.01,43173,DB00470,Dronabinol
,25752889,C max,"After the second dose (6-24 h), the C max was 0.50 (0.27-0.92) and 0.98 (0.46-2.06), respectively.","Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25752889/),,0.50,43174,DB00470,Dronabinol
,25752889,C max,"After the second dose (6-24 h), the C max was 0.50 (0.27-0.92) and 0.98 (0.46-2.06), respectively.","Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25752889/),,0.98,43175,DB00470,Dronabinol
,21875944,LOQs,"In plasma, the LOQs were 0.25 μg/L for THC and THCCOOH, and 0.5 μg/L for 11-hydroxy-THC.",Oral fluid and plasma cannabinoid ratios after around-the-clock controlled oral Δ(9)-tetrahydrocannabinol administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21875944/),[μg] / [l],0.25,48055,DB00470,Dronabinol
,21875944,LOQs,"In plasma, the LOQs were 0.25 μg/L for THC and THCCOOH, and 0.5 μg/L for 11-hydroxy-THC.",Oral fluid and plasma cannabinoid ratios after around-the-clock controlled oral Δ(9)-tetrahydrocannabinol administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21875944/),[μg] / [l],0.5,48056,DB00470,Dronabinol
,2870899,terminal half-lives,"Plasma concentration-time data were analyzed by least squares nonlinear regression with the program NONLIN and terminal half-lives in the range 30-66 hr [mean 47.1 +/- 3.5 (SE), n = 8] were found after acute drug treatment.",Pharmacokinetics of delta 9-tetrahydrocannabinol in rabbits following single or multiple intravenous doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2870899/),h,30-66,52215,DB00470,Dronabinol
,2870899,terminal half-lives,"Plasma concentration-time data were analyzed by least squares nonlinear regression with the program NONLIN and terminal half-lives in the range 30-66 hr [mean 47.1 +/- 3.5 (SE), n = 8] were found after acute drug treatment.",Pharmacokinetics of delta 9-tetrahydrocannabinol in rabbits following single or multiple intravenous doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2870899/),,47.1,52216,DB00470,Dronabinol
,15936883,Ki,"Here we show that CT-3 binds to human cannabinoid receptors in vitro, with high affinity at hCB1 (Ki 6 nM) and hCB2 (Ki 56 nM) receptors.",Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15936883/),nM,6,55117,DB00470,Dronabinol
,15936883,Ki,"Here we show that CT-3 binds to human cannabinoid receptors in vitro, with high affinity at hCB1 (Ki 6 nM) and hCB2 (Ki 56 nM) receptors.",Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15936883/),nM,56,55118,DB00470,Dronabinol
,15936883,EC50,"In a functional GTP-gamma-S assay CT-3 was an agonist at both hCB1 and hCB2 receptors (EC50 11 and 13.4 nM, respectively).",Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15936883/),nM,11,55119,DB00470,Dronabinol
,15936883,EC50,"In a functional GTP-gamma-S assay CT-3 was an agonist at both hCB1 and hCB2 receptors (EC50 11 and 13.4 nM, respectively).",Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15936883/),nM,13.4,55120,DB00470,Dronabinol
,15936883,brain/plasma ratio,"Pharmacokinetic analysis showed that CT-3 exhibits significant but limited brain penetration, with a brain/plasma ratio of 0.4 measured following oral administration, compared to ratios of 1.0-1.9 measured following subcutaneous administration of WIN55,212-2 or Delta9-THC.",Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15936883/),,0.4,55121,DB00470,Dronabinol
,11599597,half-life,No accurate prediction of time of use is possible because THC-COOH has a half-life of 6 days.,"Temporal indication of marijuana use can be estimated from plasma and urine concentrations of delta9-tetrahydrocannabinol, 11-hydroxy-delta9-tetrahydrocannabinol, and 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599597/),d,6,56283,DB00470,Dronabinol
,11599597,COOH,"One subject, who later admitted chronic marijuana use (urine baseline THCCOOH, 529.2 ng/mL; plasma, 75.5 ng/mL), excreted 8beta-dihydroxy-THC, peaking 2 h postsmoking (92.3 ng/mL).","Temporal indication of marijuana use can be estimated from plasma and urine concentrations of delta9-tetrahydrocannabinol, 11-hydroxy-delta9-tetrahydrocannabinol, and 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599597/),[ng] / [ml],529.2,56284,DB00470,Dronabinol
,11599597,COOH,"One subject, who later admitted chronic marijuana use (urine baseline THCCOOH, 529.2 ng/mL; plasma, 75.5 ng/mL), excreted 8beta-dihydroxy-THC, peaking 2 h postsmoking (92.3 ng/mL).","Temporal indication of marijuana use can be estimated from plasma and urine concentrations of delta9-tetrahydrocannabinol, 11-hydroxy-delta9-tetrahydrocannabinol, and 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599597/),ng,75,56285,DB00470,Dronabinol
,33770654,inhalation/holding time ratios,"In addition, two different puff protocols (4.0/10.0 s and 1.6/11.4 s as the inhalation/holding time ratios) were employed, associated with two different inhaled THC doses (2.0 mg and 8.82 mg, respectively).",Influences of puff protocols and upper airway anatomy on cannabis pharmacokinetics: A CFPD-PK study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33770654/),s,4.0,59201,DB00470,Dronabinol
,33770654,inhalation/holding time ratios,"In addition, two different puff protocols (4.0/10.0 s and 1.6/11.4 s as the inhalation/holding time ratios) were employed, associated with two different inhaled THC doses (2.0 mg and 8.82 mg, respectively).",Influences of puff protocols and upper airway anatomy on cannabis pharmacokinetics: A CFPD-PK study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33770654/),s,1.6,59202,DB00470,Dronabinol
,33770654,inhalation/holding time ratios,"In addition, two different puff protocols (4.0/10.0 s and 1.6/11.4 s as the inhalation/holding time ratios) were employed, associated with two different inhaled THC doses (2.0 mg and 8.82 mg, respectively).",Influences of puff protocols and upper airway anatomy on cannabis pharmacokinetics: A CFPD-PK study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33770654/),s,11.4,59203,DB00470,Dronabinol
,33770654,inhalation/holding time ratio,The results indicated that puff protocol with 4.0/10.0 s inhalation/holding time ratio would be recommended if the treatment needs THC delivery to the deeper lung.,Influences of puff protocols and upper airway anatomy on cannabis pharmacokinetics: A CFPD-PK study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33770654/),s,4.0,59204,DB00470,Dronabinol
,17410118,serum concentrations,Highest serum concentrations of CTHC were observed at the end of the infusion (336.8+/-61.7 microg/l) followed by a quick decline.,Pharmacokinetics of 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (CTHC) after intravenous administration of CTHC in healthy human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17410118/),[μg] / [l],336.8,68288,DB00470,Dronabinol
,17410118,terminal elimination half-life,"CTHC concentration could be quantified up to 96 h after administration, with a terminal elimination half-life of 17.6+/-5.5 h.",Pharmacokinetics of 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (CTHC) after intravenous administration of CTHC in healthy human subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17410118/),h,17.6,68289,DB00470,Dronabinol
,17410118,Total clearance,"Total clearance was low (91.2+/-24.0 ml/min), with renal clearance having only a minor contribution (0.136+/-0.094 ml/min).",Pharmacokinetics of 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (CTHC) after intravenous administration of CTHC in healthy human subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17410118/),[ml] / [min],91.2,68290,DB00470,Dronabinol
,17410118,renal clearance,"Total clearance was low (91.2+/-24.0 ml/min), with renal clearance having only a minor contribution (0.136+/-0.094 ml/min).",Pharmacokinetics of 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (CTHC) after intravenous administration of CTHC in healthy human subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17410118/),[ml] / [min],0.136,68291,DB00470,Dronabinol
,29300962,maximum concentrations (Cmax),"Average maximum concentrations (Cmax) of THCCOOH were 107, 335 and 713 ng/mL, and average times to maximum concentration (Tmax) were 8, 6 and 9 h for the 10, 25 and 50 mg THC doses, respectively.",Pharmacokinetic Characterization of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in Urine Following Acute Oral Cannabis Ingestion in Healthy Adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29300962/),[ng] / [ml],107,68876,DB00470,Dronabinol
,29300962,maximum concentrations (Cmax),"Average maximum concentrations (Cmax) of THCCOOH were 107, 335 and 713 ng/mL, and average times to maximum concentration (Tmax) were 8, 6 and 9 h for the 10, 25 and 50 mg THC doses, respectively.",Pharmacokinetic Characterization of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in Urine Following Acute Oral Cannabis Ingestion in Healthy Adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29300962/),[ng] / [ml],335,68877,DB00470,Dronabinol
,29300962,maximum concentrations (Cmax),"Average maximum concentrations (Cmax) of THCCOOH were 107, 335 and 713 ng/mL, and average times to maximum concentration (Tmax) were 8, 6 and 9 h for the 10, 25 and 50 mg THC doses, respectively.",Pharmacokinetic Characterization of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in Urine Following Acute Oral Cannabis Ingestion in Healthy Adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29300962/),[ng] / [ml],713,68878,DB00470,Dronabinol
,29300962,times to maximum concentration (Tmax),"Average maximum concentrations (Cmax) of THCCOOH were 107, 335 and 713 ng/mL, and average times to maximum concentration (Tmax) were 8, 6 and 9 h for the 10, 25 and 50 mg THC doses, respectively.",Pharmacokinetic Characterization of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in Urine Following Acute Oral Cannabis Ingestion in Healthy Adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29300962/),h,8,68879,DB00470,Dronabinol
,29300962,times to maximum concentration (Tmax),"Average maximum concentrations (Cmax) of THCCOOH were 107, 335 and 713 ng/mL, and average times to maximum concentration (Tmax) were 8, 6 and 9 h for the 10, 25 and 50 mg THC doses, respectively.",Pharmacokinetic Characterization of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in Urine Following Acute Oral Cannabis Ingestion in Healthy Adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29300962/),h,6,68880,DB00470,Dronabinol
,29300962,times to maximum concentration (Tmax),"Average maximum concentrations (Cmax) of THCCOOH were 107, 335 and 713 ng/mL, and average times to maximum concentration (Tmax) were 8, 6 and 9 h for the 10, 25 and 50 mg THC doses, respectively.",Pharmacokinetic Characterization of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in Urine Following Acute Oral Cannabis Ingestion in Healthy Adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29300962/),h,9,68881,DB00470,Dronabinol
,26505163,tmax,Δ9-THC was well absorbed with a mean tmax of 123 min.,"Single dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26505163/),min,123,75694,DB00470,Dronabinol
,28736128,oral bioavailability,"Both molecules are poorly water soluble and subjected to extensive first pass metabolism in the gastrointestinal tract, leading to a limited oral bioavailability of approximately 9%.",The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28736128/),%,9,85503,DB00470,Dronabinol
,24202191,maximum concentrations,"No obvious differences were found between both groups concerning THC median maximum concentrations measured either in blood or in OF; these levels were equal to 1,338 and 1,041 μg/L in OF and to 82 and 94 μg/L in WB for occasional and heavy smokers, respectively.",Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24202191/),[μg] / [l],"1,338",86361,DB00470,Dronabinol
,24202191,maximum concentrations,"No obvious differences were found between both groups concerning THC median maximum concentrations measured either in blood or in OF; these levels were equal to 1,338 and 1,041 μg/L in OF and to 82 and 94 μg/L in WB for occasional and heavy smokers, respectively.",Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24202191/),[μg] / [l],"1,041",86362,DB00470,Dronabinol
,24202191,maximum concentrations,"No obvious differences were found between both groups concerning THC median maximum concentrations measured either in blood or in OF; these levels were equal to 1,338 and 1,041 μg/L in OF and to 82 and 94 μg/L in WB for occasional and heavy smokers, respectively.",Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24202191/),[μg] / [l],82,86363,DB00470,Dronabinol
,24202191,maximum concentrations,"No obvious differences were found between both groups concerning THC median maximum concentrations measured either in blood or in OF; these levels were equal to 1,338 and 1,041 μg/L in OF and to 82 and 94 μg/L in WB for occasional and heavy smokers, respectively.",Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24202191/),[μg] / [l],94,86364,DB00470,Dronabinol
,16356335,limits of detection,"The limits of detection were between 0.15 and 0.29 ng/mL for THC, 11-OH-THC, THC-COOH, and CBD and 1.1 ng/mL for CBN.","Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16356335/),[ng] / [ml],0.15 and 0.29,91078,DB00470,Dronabinol
,16356335,limits of detection,"The limits of detection were between 0.15 and 0.29 ng/mL for THC, 11-OH-THC, THC-COOH, and CBD and 1.1 ng/mL for CBN.","Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16356335/),[ng] / [ml],1.1,91079,DB00470,Dronabinol
,16356335,maximum plasma concentrations,"The maximum plasma concentrations after cannabis extract administration ranged between 1.2 and 10.3 ng/mL (mean 4.05 ng/mL) for THC, 1.8 and 12.3 ng/mL (mean 4.9 ng/mL) for 11-OH-THC, 19 and 71 ng/mL (mean 35 ng/mL) for THC-COOH, and 0.2 and 2.6 ng/mL (mean 0.95 ng/mg) for CBD.","Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16356335/),[ng] / [ml],4.05,91080,DB00470,Dronabinol
,16356335,maximum plasma concentrations,"The maximum plasma concentrations after cannabis extract administration ranged between 1.2 and 10.3 ng/mL (mean 4.05 ng/mL) for THC, 1.8 and 12.3 ng/mL (mean 4.9 ng/mL) for 11-OH-THC, 19 and 71 ng/mL (mean 35 ng/mL) for THC-COOH, and 0.2 and 2.6 ng/mL (mean 0.95 ng/mg) for CBD.","Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16356335/),[ng] / [ml],1.8,91081,DB00470,Dronabinol
,16356335,maximum plasma concentrations,"The maximum plasma concentrations after cannabis extract administration ranged between 1.2 and 10.3 ng/mL (mean 4.05 ng/mL) for THC, 1.8 and 12.3 ng/mL (mean 4.9 ng/mL) for 11-OH-THC, 19 and 71 ng/mL (mean 35 ng/mL) for THC-COOH, and 0.2 and 2.6 ng/mL (mean 0.95 ng/mg) for CBD.","Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16356335/),[ng] / [ml],12,91082,DB00470,Dronabinol
,16356335,maximum plasma concentrations,"The maximum plasma concentrations after cannabis extract administration ranged between 1.2 and 10.3 ng/mL (mean 4.05 ng/mL) for THC, 1.8 and 12.3 ng/mL (mean 4.9 ng/mL) for 11-OH-THC, 19 and 71 ng/mL (mean 35 ng/mL) for THC-COOH, and 0.2 and 2.6 ng/mL (mean 0.95 ng/mg) for CBD.","Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16356335/),[ng] / [ml],4.9,91083,DB00470,Dronabinol
,16356335,maximum plasma concentrations,"The maximum plasma concentrations after cannabis extract administration ranged between 1.2 and 10.3 ng/mL (mean 4.05 ng/mL) for THC, 1.8 and 12.3 ng/mL (mean 4.9 ng/mL) for 11-OH-THC, 19 and 71 ng/mL (mean 35 ng/mL) for THC-COOH, and 0.2 and 2.6 ng/mL (mean 0.95 ng/mg) for CBD.","Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16356335/),[ng] / [ml],19,91084,DB00470,Dronabinol
,16356335,maximum plasma concentrations,"The maximum plasma concentrations after cannabis extract administration ranged between 1.2 and 10.3 ng/mL (mean 4.05 ng/mL) for THC, 1.8 and 12.3 ng/mL (mean 4.9 ng/mL) for 11-OH-THC, 19 and 71 ng/mL (mean 35 ng/mL) for THC-COOH, and 0.2 and 2.6 ng/mL (mean 0.95 ng/mg) for CBD.","Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16356335/),[ng] / [ml],71,91085,DB00470,Dronabinol
,16356335,maximum plasma concentrations,"The maximum plasma concentrations after cannabis extract administration ranged between 1.2 and 10.3 ng/mL (mean 4.05 ng/mL) for THC, 1.8 and 12.3 ng/mL (mean 4.9 ng/mL) for 11-OH-THC, 19 and 71 ng/mL (mean 35 ng/mL) for THC-COOH, and 0.2 and 2.6 ng/mL (mean 0.95 ng/mg) for CBD.","Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16356335/),[ng] / [ml],35,91086,DB00470,Dronabinol
,16356335,maximum plasma concentrations,"The maximum plasma concentrations after cannabis extract administration ranged between 1.2 and 10.3 ng/mL (mean 4.05 ng/mL) for THC, 1.8 and 12.3 ng/mL (mean 4.9 ng/mL) for 11-OH-THC, 19 and 71 ng/mL (mean 35 ng/mL) for THC-COOH, and 0.2 and 2.6 ng/mL (mean 0.95 ng/mg) for CBD.","Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16356335/),[ng] / [ml],0,91087,DB00470,Dronabinol
,16356335,maximum plasma concentrations,"The maximum plasma concentrations after cannabis extract administration ranged between 1.2 and 10.3 ng/mL (mean 4.05 ng/mL) for THC, 1.8 and 12.3 ng/mL (mean 4.9 ng/mL) for 11-OH-THC, 19 and 71 ng/mL (mean 35 ng/mL) for THC-COOH, and 0.2 and 2.6 ng/mL (mean 0.95 ng/mg) for CBD.","Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16356335/),[ng] / [mg],0.95,91088,DB00470,Dronabinol
,28399267,concentration,The concentration of THC in the iris-ciliary bodies at the 60- and 120-minute time points (53 and 57.4 ng/50 mg) were significantly greater than that of THC-Val-HS (24.2 and 11.3 ng/50 mg).,Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28399267/),,24.2,91446,DB00470,Dronabinol
,28399267,concentration,The concentration of THC in the iris-ciliary bodies at the 60- and 120-minute time points (53 and 57.4 ng/50 mg) were significantly greater than that of THC-Val-HS (24.2 and 11.3 ng/50 mg).,Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28399267/),,11,91447,DB00470,Dronabinol
up to,23429905,Maximum concentrations,"Maximum concentrations of tetrahydrocannabinol (THC) immediately after smoking (up to 44,412 ng/g) were below 4,300 (median 377) ng/g 1 h after smoking and less than 312 (median 88) ng/g 3 h later with 5 of 49 samples negative, suggesting that recent cannabis use might occasionally not be detectable.",Influence of ethanol on the pharmacokinetic properties of Δ9-tetrahydrocannabinol in oral fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23429905/),[ng] / [g],"44,412",96870,DB00470,Dronabinol
below,23429905,Maximum concentrations,"Maximum concentrations of tetrahydrocannabinol (THC) immediately after smoking (up to 44,412 ng/g) were below 4,300 (median 377) ng/g 1 h after smoking and less than 312 (median 88) ng/g 3 h later with 5 of 49 samples negative, suggesting that recent cannabis use might occasionally not be detectable.",Influence of ethanol on the pharmacokinetic properties of Δ9-tetrahydrocannabinol in oral fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23429905/),[ng] / [g],"4,300",96871,DB00470,Dronabinol
less,23429905,Maximum concentrations,"Maximum concentrations of tetrahydrocannabinol (THC) immediately after smoking (up to 44,412 ng/g) were below 4,300 (median 377) ng/g 1 h after smoking and less than 312 (median 88) ng/g 3 h later with 5 of 49 samples negative, suggesting that recent cannabis use might occasionally not be detectable.",Influence of ethanol on the pharmacokinetic properties of Δ9-tetrahydrocannabinol in oral fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23429905/),[ng] / [g],312,96872,DB00470,Dronabinol
,6250760,systemic availability,Based on AUC0-360 min systemic availability of THC after smoking was estimated to be 18 +/- 6%.,Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6250760/),%,18,98085,DB00470,Dronabinol
,6250760,systemic availability,Oral THC in a chocolate cookie provided systemic availability of 6 +/- 3%.,Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6250760/),%,6,98086,DB00470,Dronabinol
,18847571,bioavailability,After smoking THC bioavailability averages 30%.,[Delta-9-tetrahydrocannabinol pharmacokinetics]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18847571/),%,30,100625,DB00470,Dronabinol
,18847571,peak plasma level,"With a 3.55% THC cigarette, a peak plasma level near 160 ng/mL occurs approximately 10 min after inhalation.",[Delta-9-tetrahydrocannabinol pharmacokinetics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18847571/),[ng] / [ml],160,100626,DB00470,Dronabinol
,32587099,fraction unbound,"The fraction unbound of CBD and THC in the incubation mixture was 0.12 ± 0.04 and 0.05 ± 0.02, respectively.",Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32587099/),,0.12,102632,DB00470,Dronabinol
,32587099,fraction unbound,"The fraction unbound of CBD and THC in the incubation mixture was 0.12 ± 0.04 and 0.05 ± 0.02, respectively.",Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32587099/),,0.05,102633,DB00470,Dronabinol
,32587099,"IC50,u","The IC50,u for CBD toward CYP1A2, 2C9, 2C19, 2D6, and 3A was 0.45 ± 0.17, 0.17 ± 0.03, 0.30 ± 0.06, 0.95 ± 0.50, and 0.38 ± 0.11 µM, respectively; the IC50,u for THC was 0.06 ± 0.02, 0.012 ± 0.001, 0.57 ± 0.22, 1.28 ± 0.25, and 1.30 ± 0.34 µM, respectively.",Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32587099/),μM,0.45,102634,DB00470,Dronabinol
,32587099,"IC50,u","The IC50,u for CBD toward CYP1A2, 2C9, 2C19, 2D6, and 3A was 0.45 ± 0.17, 0.17 ± 0.03, 0.30 ± 0.06, 0.95 ± 0.50, and 0.38 ± 0.11 µM, respectively; the IC50,u for THC was 0.06 ± 0.02, 0.012 ± 0.001, 0.57 ± 0.22, 1.28 ± 0.25, and 1.30 ± 0.34 µM, respectively.",Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32587099/),μM,0.17,102635,DB00470,Dronabinol
,32587099,"IC50,u","The IC50,u for CBD toward CYP1A2, 2C9, 2C19, 2D6, and 3A was 0.45 ± 0.17, 0.17 ± 0.03, 0.30 ± 0.06, 0.95 ± 0.50, and 0.38 ± 0.11 µM, respectively; the IC50,u for THC was 0.06 ± 0.02, 0.012 ± 0.001, 0.57 ± 0.22, 1.28 ± 0.25, and 1.30 ± 0.34 µM, respectively.",Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32587099/),μM,0.30,102636,DB00470,Dronabinol
,32587099,"IC50,u","The IC50,u for CBD toward CYP1A2, 2C9, 2C19, 2D6, and 3A was 0.45 ± 0.17, 0.17 ± 0.03, 0.30 ± 0.06, 0.95 ± 0.50, and 0.38 ± 0.11 µM, respectively; the IC50,u for THC was 0.06 ± 0.02, 0.012 ± 0.001, 0.57 ± 0.22, 1.28 ± 0.25, and 1.30 ± 0.34 µM, respectively.",Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32587099/),μM,0.95,102637,DB00470,Dronabinol
,32587099,"IC50,u","The IC50,u for CBD toward CYP1A2, 2C9, 2C19, 2D6, and 3A was 0.45 ± 0.17, 0.17 ± 0.03, 0.30 ± 0.06, 0.95 ± 0.50, and 0.38 ± 0.11 µM, respectively; the IC50,u for THC was 0.06 ± 0.02, 0.012 ± 0.001, 0.57 ± 0.22, 1.28 ± 0.25, and 1.30 ± 0.34 µM, respectively.",Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32587099/),μM,0.38,102638,DB00470,Dronabinol
,32587099,"IC50,u","The IC50,u for CBD toward CYP1A2, 2C9, 2C19, 2D6, and 3A was 0.45 ± 0.17, 0.17 ± 0.03, 0.30 ± 0.06, 0.95 ± 0.50, and 0.38 ± 0.11 µM, respectively; the IC50,u for THC was 0.06 ± 0.02, 0.012 ± 0.001, 0.57 ± 0.22, 1.28 ± 0.25, and 1.30 ± 0.34 µM, respectively.",Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32587099/),μM,0.06,102639,DB00470,Dronabinol
,32587099,"IC50,u","The IC50,u for CBD toward CYP1A2, 2C9, 2C19, 2D6, and 3A was 0.45 ± 0.17, 0.17 ± 0.03, 0.30 ± 0.06, 0.95 ± 0.50, and 0.38 ± 0.11 µM, respectively; the IC50,u for THC was 0.06 ± 0.02, 0.012 ± 0.001, 0.57 ± 0.22, 1.28 ± 0.25, and 1.30 ± 0.34 µM, respectively.",Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32587099/),μM,0.012,102640,DB00470,Dronabinol
,32587099,"IC50,u","The IC50,u for CBD toward CYP1A2, 2C9, 2C19, 2D6, and 3A was 0.45 ± 0.17, 0.17 ± 0.03, 0.30 ± 0.06, 0.95 ± 0.50, and 0.38 ± 0.11 µM, respectively; the IC50,u for THC was 0.06 ± 0.02, 0.012 ± 0.001, 0.57 ± 0.22, 1.28 ± 0.25, and 1.30 ± 0.34 µM, respectively.",Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32587099/),μM,0.57,102641,DB00470,Dronabinol
,32587099,"IC50,u","The IC50,u for CBD toward CYP1A2, 2C9, 2C19, 2D6, and 3A was 0.45 ± 0.17, 0.17 ± 0.03, 0.30 ± 0.06, 0.95 ± 0.50, and 0.38 ± 0.11 µM, respectively; the IC50,u for THC was 0.06 ± 0.02, 0.012 ± 0.001, 0.57 ± 0.22, 1.28 ± 0.25, and 1.30 ± 0.34 µM, respectively.",Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32587099/),μM,1.28,102642,DB00470,Dronabinol
,32587099,"IC50,u","The IC50,u for CBD toward CYP1A2, 2C9, 2C19, 2D6, and 3A was 0.45 ± 0.17, 0.17 ± 0.03, 0.30 ± 0.06, 0.95 ± 0.50, and 0.38 ± 0.11 µM, respectively; the IC50,u for THC was 0.06 ± 0.02, 0.012 ± 0.001, 0.57 ± 0.22, 1.28 ± 0.25, and 1.30 ± 0.34 µM, respectively.",Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32587099/),μM,1.30,102643,DB00470,Dronabinol
,32587099,"inactivation efficiencies (k inact/K I,u)","Only CBD showed time-dependent inactivation (TDI) of CYP1A2, 2C19, and CYP3A, with inactivation efficiencies (k inact/K I,u) of 0.70 ± 0.34, 0.11 ± 0.06, and 0.14 ± 0.04 minutes-1 µM-1, respectively.",Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32587099/),1/[min·μM],0.70,102644,DB00470,Dronabinol
,32587099,"inactivation efficiencies (k inact/K I,u)","Only CBD showed time-dependent inactivation (TDI) of CYP1A2, 2C19, and CYP3A, with inactivation efficiencies (k inact/K I,u) of 0.70 ± 0.34, 0.11 ± 0.06, and 0.14 ± 0.04 minutes-1 µM-1, respectively.",Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32587099/),1/[min·μM],0.11,102645,DB00470,Dronabinol
,32587099,"inactivation efficiencies (k inact/K I,u)","Only CBD showed time-dependent inactivation (TDI) of CYP1A2, 2C19, and CYP3A, with inactivation efficiencies (k inact/K I,u) of 0.70 ± 0.34, 0.11 ± 0.06, and 0.14 ± 0.04 minutes-1 µM-1, respectively.",Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32587099/),1/[min·μM],0.14,102646,DB00470,Dronabinol
,15866495,glucuronide concentration,The mean AJA glucuronide concentration at 2h was 63.8+/-127.9 ng/ml.,Determination of ajulemic acid and its glucuronide in human plasma by gas chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866495/),[ng] / [ml],63.8,104763,DB00470,Dronabinol
,12404700,plasma,"In these studies, plasma THC ranged from 9.5x10(12) M to 2.4x10(14) M.","Pharmacokinetics of THC in brain and testis, male gametotoxicity and premature apoptosis of spermatozoa. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404700/),M,9.5x10(12),105249,DB00470,Dronabinol
,12404700,THC,"In these studies, plasma THC ranged from 9.5x10(12) M to 2.4x10(14) M.","Pharmacokinetics of THC in brain and testis, male gametotoxicity and premature apoptosis of spermatozoa. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404700/),M,9.5x10(12),105250,DB00470,Dronabinol
,12404700,THC,"In these studies, plasma THC ranged from 9.5x10(12) M to 2.4x10(14) M.","Pharmacokinetics of THC in brain and testis, male gametotoxicity and premature apoptosis of spermatozoa. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404700/),M,2.4x10(14),105251,DB00470,Dronabinol
,2998394,ED50,"In rats trained in a water maze to discriminate between i.p. injections of 3 mg/kg delta 9-THC (ED50 = 1.8 mg/kg) and its vehicle, the amide was generalized to the training drug, being five times less potent (ED50 = 8.7 mg/kg) than delta 9-THC.","N-Ethyl-17(R,S)-methyl-(6aR,10aR)-delta 8-tetrahydrocannabinol-18-oic amide. Brain pharmacokinetics in mice, triglyceride/phospholipid partitioning and generalization to the discriminative stimulus properties of delta 9-THC in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2998394/),[mg] / [kg],1.8,107174,DB00470,Dronabinol
,2998394,ED50,"In rats trained in a water maze to discriminate between i.p. injections of 3 mg/kg delta 9-THC (ED50 = 1.8 mg/kg) and its vehicle, the amide was generalized to the training drug, being five times less potent (ED50 = 8.7 mg/kg) than delta 9-THC.","N-Ethyl-17(R,S)-methyl-(6aR,10aR)-delta 8-tetrahydrocannabinol-18-oic amide. Brain pharmacokinetics in mice, triglyceride/phospholipid partitioning and generalization to the discriminative stimulus properties of delta 9-THC in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2998394/),[mg] / [kg],8.7,107175,DB00470,Dronabinol
,28138268,time to the first measurable concentration,"In the fed state, initial dronabinol absorption was faster with oral solution versus capsule (mean time to the first measurable concentration, 0.15 vs 2.02 hours, respectively), with 100% and 15% of volunteers, respectively, having detectable plasma dronabinol levels 30 minutes postdose.",Effect of food on the pharmacokinetics of dronabinol oral solution versus dronabinol capsules in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28138268/),h,0.15,108369,DB00470,Dronabinol
,28138268,time to the first measurable concentration,"In the fed state, initial dronabinol absorption was faster with oral solution versus capsule (mean time to the first measurable concentration, 0.15 vs 2.02 hours, respectively), with 100% and 15% of volunteers, respectively, having detectable plasma dronabinol levels 30 minutes postdose.",Effect of food on the pharmacokinetics of dronabinol oral solution versus dronabinol capsules in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28138268/),h,2.02,108370,DB00470,Dronabinol
,28138268,time to maximum plasma concentration,Mean time to maximum plasma concentration was similarly delayed for dronabinol oral solution with food (7.7 hours) and capsule with food (5.6 hours) versus capsule with fasting (1.7 hours).,Effect of food on the pharmacokinetics of dronabinol oral solution versus dronabinol capsules in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28138268/),h,7.7,108371,DB00470,Dronabinol
,28138268,time to maximum plasma concentration,Mean time to maximum plasma concentration was similarly delayed for dronabinol oral solution with food (7.7 hours) and capsule with food (5.6 hours) versus capsule with fasting (1.7 hours).,Effect of food on the pharmacokinetics of dronabinol oral solution versus dronabinol capsules in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28138268/),h,5.6,108372,DB00470,Dronabinol
,28138268,time to maximum plasma concentration,Mean time to maximum plasma concentration was similarly delayed for dronabinol oral solution with food (7.7 hours) and capsule with food (5.6 hours) versus capsule with fasting (1.7 hours).,Effect of food on the pharmacokinetics of dronabinol oral solution versus dronabinol capsules in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28138268/),h,1.7,108373,DB00470,Dronabinol
,1662560,limit of detection,"Using a trifluoroacetic anhydride derivatization procedure and the High Energy Dynode detector system, we improved by 6.25-fold the limit of detection for delta-9-tetrahydrocannabinol in plasma over that obtained with the same GC/MS system without the new detector (80 vs 500 ng/L).",Ultrasensitive measurement of delta-9-tetrahydrocannabinol with a high energy dynode detector and electron-capture negative chemical-ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662560/),[ng] / [l],80,111033,DB00470,Dronabinol
,1662560,limit of detection,"Using a trifluoroacetic anhydride derivatization procedure and the High Energy Dynode detector system, we improved by 6.25-fold the limit of detection for delta-9-tetrahydrocannabinol in plasma over that obtained with the same GC/MS system without the new detector (80 vs 500 ng/L).",Ultrasensitive measurement of delta-9-tetrahydrocannabinol with a high energy dynode detector and electron-capture negative chemical-ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662560/),[ng] / [l],500,111034,DB00470,Dronabinol
,34089060,Cmax,"Urinary CBD concentrations (ng/mL) were higher after oral (mean Cmax: 734; mean Tmax: 4.7 h, n=18) versus vaporized CBD (mean Cmax: 240; mean Tmax: 1.3 h, n=18), and oral dose formulation significantly impacted mean Cmax (Epidiolex=1274 ng/mL, capsule=776 ng/mL, syrup=151 ng/mL, n=6/group) with little difference in Tmax.","Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC), and their Metabolites Following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34089060/),,734,112847,DB00470,Dronabinol
,34089060,Tmax,"Urinary CBD concentrations (ng/mL) were higher after oral (mean Cmax: 734; mean Tmax: 4.7 h, n=18) versus vaporized CBD (mean Cmax: 240; mean Tmax: 1.3 h, n=18), and oral dose formulation significantly impacted mean Cmax (Epidiolex=1274 ng/mL, capsule=776 ng/mL, syrup=151 ng/mL, n=6/group) with little difference in Tmax.","Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC), and their Metabolites Following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34089060/),h,4.7,112848,DB00470,Dronabinol
,34089060,Cmax,"Urinary CBD concentrations (ng/mL) were higher after oral (mean Cmax: 734; mean Tmax: 4.7 h, n=18) versus vaporized CBD (mean Cmax: 240; mean Tmax: 1.3 h, n=18), and oral dose formulation significantly impacted mean Cmax (Epidiolex=1274 ng/mL, capsule=776 ng/mL, syrup=151 ng/mL, n=6/group) with little difference in Tmax.","Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC), and their Metabolites Following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34089060/),,240,112849,DB00470,Dronabinol
,34089060,Tmax,"Urinary CBD concentrations (ng/mL) were higher after oral (mean Cmax: 734; mean Tmax: 4.7 h, n=18) versus vaporized CBD (mean Cmax: 240; mean Tmax: 1.3 h, n=18), and oral dose formulation significantly impacted mean Cmax (Epidiolex=1274 ng/mL, capsule=776 ng/mL, syrup=151 ng/mL, n=6/group) with little difference in Tmax.","Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC), and their Metabolites Following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34089060/),h,1.3,112850,DB00470,Dronabinol
,34089060,Cmax,"Urinary CBD concentrations (ng/mL) were higher after oral (mean Cmax: 734; mean Tmax: 4.7 h, n=18) versus vaporized CBD (mean Cmax: 240; mean Tmax: 1.3 h, n=18), and oral dose formulation significantly impacted mean Cmax (Epidiolex=1274 ng/mL, capsule=776 ng/mL, syrup=151 ng/mL, n=6/group) with little difference in Tmax.","Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC), and their Metabolites Following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34089060/),[ng] / [ml],1274,112851,DB00470,Dronabinol
,34089060,Cmax,"Urinary CBD concentrations (ng/mL) were higher after oral (mean Cmax: 734; mean Tmax: 4.7 h, n=18) versus vaporized CBD (mean Cmax: 240; mean Tmax: 1.3 h, n=18), and oral dose formulation significantly impacted mean Cmax (Epidiolex=1274 ng/mL, capsule=776 ng/mL, syrup=151 ng/mL, n=6/group) with little difference in Tmax.","Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC), and their Metabolites Following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34089060/),[ng] / [ml],776,112852,DB00470,Dronabinol
,34089060,Cmax,"Urinary CBD concentrations (ng/mL) were higher after oral (mean Cmax: 734; mean Tmax: 4.7 h, n=18) versus vaporized CBD (mean Cmax: 240; mean Tmax: 1.3 h, n=18), and oral dose formulation significantly impacted mean Cmax (Epidiolex=1274 ng/mL, capsule=776 ng/mL, syrup=151 ng/mL, n=6/group) with little difference in Tmax.","Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC), and their Metabolites Following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34089060/),[ng] / [ml],151,112853,DB00470,Dronabinol
,32054131,Cmax,Maximal plasma concentrations of both Δ9-THC (Cmax = 18.5 ng/mL) and CBD (Cmax = 10.5 ng/mL) were achieved 2 h after administration in the single dose condition and at 1 h in the multiple dose treatment (Δ9-THC: Cmax = 24.5 ng/mL; CBD: Cmax = 15.2 ng/mL).,Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32054131/),[ng] / [ml],18.5,113322,DB00470,Dronabinol
,32054131,Cmax,Maximal plasma concentrations of both Δ9-THC (Cmax = 18.5 ng/mL) and CBD (Cmax = 10.5 ng/mL) were achieved 2 h after administration in the single dose condition and at 1 h in the multiple dose treatment (Δ9-THC: Cmax = 24.5 ng/mL; CBD: Cmax = 15.2 ng/mL).,Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32054131/),[ng] / [ml],10.5,113323,DB00470,Dronabinol
,32054131,Cmax,Maximal plasma concentrations of both Δ9-THC (Cmax = 18.5 ng/mL) and CBD (Cmax = 10.5 ng/mL) were achieved 2 h after administration in the single dose condition and at 1 h in the multiple dose treatment (Δ9-THC: Cmax = 24.5 ng/mL; CBD: Cmax = 15.2 ng/mL).,Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32054131/),[ng] / [ml],24.5,113324,DB00470,Dronabinol
,32054131,Cmax,Maximal plasma concentrations of both Δ9-THC (Cmax = 18.5 ng/mL) and CBD (Cmax = 10.5 ng/mL) were achieved 2 h after administration in the single dose condition and at 1 h in the multiple dose treatment (Δ9-THC: Cmax = 24.5 ng/mL; CBD: Cmax = 15.2 ng/mL).,Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32054131/),[ng] / [ml],15.2,113325,DB00470,Dronabinol
,30580232,Tmax,Fed dogs showed a longer absorption phase (Tmax 5 vs 1.25 h) and lower maximal blood concentration (7.1 vs 24 ng/mL) compared with the fasted group.,"Pharmacokinetics of Bedrocan®, a cannabis oil extract, in fasting and fed dogs: An explorative study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30580232/),h,5,115598,DB00470,Dronabinol
,30580232,Tmax,Fed dogs showed a longer absorption phase (Tmax 5 vs 1.25 h) and lower maximal blood concentration (7.1 vs 24 ng/mL) compared with the fasted group.,"Pharmacokinetics of Bedrocan®, a cannabis oil extract, in fasting and fed dogs: An explorative study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30580232/),h,1.25,115599,DB00470,Dronabinol
,30580232,maximal blood concentration,Fed dogs showed a longer absorption phase (Tmax 5 vs 1.25 h) and lower maximal blood concentration (7.1 vs 24 ng/mL) compared with the fasted group.,"Pharmacokinetics of Bedrocan®, a cannabis oil extract, in fasting and fed dogs: An explorative study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30580232/),[ng] / [ml],7.1,115600,DB00470,Dronabinol
,30580232,maximal blood concentration,Fed dogs showed a longer absorption phase (Tmax 5 vs 1.25 h) and lower maximal blood concentration (7.1 vs 24 ng/mL) compared with the fasted group.,"Pharmacokinetics of Bedrocan®, a cannabis oil extract, in fasting and fed dogs: An explorative study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30580232/),[ng] / [ml],24,115601,DB00470,Dronabinol
,30580232,relative oral bioavailability,A larger AUC was found in the fasted group; the relative oral bioavailability in fed animals was 48.22%.,"Pharmacokinetics of Bedrocan®, a cannabis oil extract, in fasting and fed dogs: An explorative study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30580232/),%,48.22,115602,DB00470,Dronabinol
,33635755,bioavailability,The bioavailability of inhaled THC is 10% to 35%.,Mechanisms of Action and Pharmacokinetics of Cannabis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33635755/),%,10,116144,DB00470,Dronabinol
,33635755,bioavailability,The bioavailability of ingested THC is only 4% to 12%.,Mechanisms of Action and Pharmacokinetics of Cannabis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33635755/),%,4,116145,DB00470,Dronabinol
,33635755,bioavailability,The bioavailability of ingested THC is only 4% to 12%.,Mechanisms of Action and Pharmacokinetics of Cannabis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33635755/),%,12,116146,DB00470,Dronabinol
,33635755,plasma half-life,The plasma half-life of THC is 1 to 3 days in occasional users and 5 to 13 days in chronic users.,Mechanisms of Action and Pharmacokinetics of Cannabis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33635755/),d,1 to 3,116147,DB00470,Dronabinol
,33635755,plasma half-life,The plasma half-life of THC is 1 to 3 days in occasional users and 5 to 13 days in chronic users.,Mechanisms of Action and Pharmacokinetics of Cannabis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33635755/),d,5 to 13,116148,DB00470,Dronabinol
,33635755,bioavailability,"The bioavailability of CBD via inhalation is 11% to 45%, whereas that of oral CBD is 6%.",Mechanisms of Action and Pharmacokinetics of Cannabis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33635755/),%,11,116149,DB00470,Dronabinol
,33635755,bioavailability,"The bioavailability of CBD via inhalation is 11% to 45%, whereas that of oral CBD is 6%.",Mechanisms of Action and Pharmacokinetics of Cannabis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33635755/),%,45,116150,DB00470,Dronabinol
,33635755,bioavailability,"The bioavailability of CBD via inhalation is 11% to 45%, whereas that of oral CBD is 6%.",Mechanisms of Action and Pharmacokinetics of Cannabis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33635755/),%,6,116151,DB00470,Dronabinol
,33635755,plasma half-life,The plasma half-life of CBD is 18 to 32 hours.,Mechanisms of Action and Pharmacokinetics of Cannabis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33635755/),h,18 to 32,116152,DB00470,Dronabinol
,32728233,maximum concentration,The geometric mean maximum concentration of CBDA of 72.7 ng/mL was observed at 14 h after administration.,Plasma concentrations of eleven cannabinoids in cattle following oral administration of industrial hemp (Cannabis sativa). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32728233/),[ng] / [ml],72.7,117069,DB00470,Dronabinol
,32728233,half-life,The geometric mean half-life of CBDA was 14.1 h.,Plasma concentrations of eleven cannabinoids in cattle following oral administration of industrial hemp (Cannabis sativa). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32728233/),h,14.1,117070,DB00470,Dronabinol
,2561839,elimination half-life,An average elimination half-life (+/- SD) of 3.0 +/- 2.3 days was obtained for delta 1-THC-7-oic acid.,Urinary elimination half-life of delta-1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2561839/),d,3.0,118697,DB00470,Dronabinol
,30567877,f m,"As previously reported, CYP2C9 was the major enzyme responsible for depletion of THC and formation of 11-OH-THC with f m values of 0.82 ± 0.08 and 0.99 ± 0.10, respectively (mean ± S.D.), while CYP2D6 and CYP2C19 were minor contributors.","Hepatic Enzymes Relevant to the Disposition of (-)-∆9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30567877/),,0.82,120313,DB00470,Dronabinol
,30567877,f m,"As previously reported, CYP2C9 was the major enzyme responsible for depletion of THC and formation of 11-OH-THC with f m values of 0.82 ± 0.08 and 0.99 ± 0.10, respectively (mean ± S.D.), while CYP2D6 and CYP2C19 were minor contributors.","Hepatic Enzymes Relevant to the Disposition of (-)-∆9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30567877/),,0.99,120314,DB00470,Dronabinol
,30567877,f m,"11-OH-THC was depleted by UGT and P450 enzymes with f m values of 0.60 ± 0.05 and 0.40 ± 0.05, respectively (mean ± S.D.), with UGT2B7, UGT1A9, CYP2C9, and CYP3A4 as contributors.","Hepatic Enzymes Relevant to the Disposition of (-)-∆9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30567877/),,0.60,120315,DB00470,Dronabinol
,30567877,f m,"11-OH-THC was depleted by UGT and P450 enzymes with f m values of 0.60 ± 0.05 and 0.40 ± 0.05, respectively (mean ± S.D.), with UGT2B7, UGT1A9, CYP2C9, and CYP3A4 as contributors.","Hepatic Enzymes Relevant to the Disposition of (-)-∆9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30567877/),,0.40,120316,DB00470,Dronabinol
,31048453,fm,"CYP2C9 pathway was the major pathway for depletion of THC (fm = 0.91, Km,u = 3 nM) and formation of 11-OH-THC.","Quantifying Hepatic Enzyme Kinetics of (-)-∆9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC, through In Vitro Modeling. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31048453/),,0.91,121955,DB00470,Dronabinol
,31048453,"Km,u","CYP2C9 pathway was the major pathway for depletion of THC (fm = 0.91, Km,u = 3 nM) and formation of 11-OH-THC.","Quantifying Hepatic Enzyme Kinetics of (-)-∆9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC, through In Vitro Modeling. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31048453/),nM,3,121956,DB00470,Dronabinol
,31048453,fm,"11-OH-THC was depleted by UGTs (fm = 0.67 and Km,u = 39 nM), CYP3A4 (fm = 0.18, Km,u = 824 nM), and CYP2C9 (fm = 0.15, Km,u = 33 nM).","Quantifying Hepatic Enzyme Kinetics of (-)-∆9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC, through In Vitro Modeling. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31048453/),,0.67,121957,DB00470,Dronabinol
,31048453,"Km,u","11-OH-THC was depleted by UGTs (fm = 0.67 and Km,u = 39 nM), CYP3A4 (fm = 0.18, Km,u = 824 nM), and CYP2C9 (fm = 0.15, Km,u = 33 nM).","Quantifying Hepatic Enzyme Kinetics of (-)-∆9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC, through In Vitro Modeling. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31048453/),nM,39,121958,DB00470,Dronabinol
,31048453,fm,"11-OH-THC was depleted by UGTs (fm = 0.67 and Km,u = 39 nM), CYP3A4 (fm = 0.18, Km,u = 824 nM), and CYP2C9 (fm = 0.15, Km,u = 33 nM).","Quantifying Hepatic Enzyme Kinetics of (-)-∆9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC, through In Vitro Modeling. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31048453/),,0.18,121959,DB00470,Dronabinol
,31048453,"Km,u","11-OH-THC was depleted by UGTs (fm = 0.67 and Km,u = 39 nM), CYP3A4 (fm = 0.18, Km,u = 824 nM), and CYP2C9 (fm = 0.15, Km,u = 33 nM).","Quantifying Hepatic Enzyme Kinetics of (-)-∆9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC, through In Vitro Modeling. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31048453/),nM,824,121960,DB00470,Dronabinol
,31048453,fm,"11-OH-THC was depleted by UGTs (fm = 0.67 and Km,u = 39 nM), CYP3A4 (fm = 0.18, Km,u = 824 nM), and CYP2C9 (fm = 0.15, Km,u = 33 nM).","Quantifying Hepatic Enzyme Kinetics of (-)-∆9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC, through In Vitro Modeling. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31048453/),,0.15,121961,DB00470,Dronabinol
,31048453,"Km,u","11-OH-THC was depleted by UGTs (fm = 0.67 and Km,u = 39 nM), CYP3A4 (fm = 0.18, Km,u = 824 nM), and CYP2C9 (fm = 0.15, Km,u = 33 nM).","Quantifying Hepatic Enzyme Kinetics of (-)-∆9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC, through In Vitro Modeling. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31048453/),nM,33,121962,DB00470,Dronabinol
,6270295,total (metabolic) blood clearance,"The total (metabolic) blood clearance of THC averaged 17.4 ml/min/kg without CBD and 20.9 ml/min/kg with CBD, and was probably hepatic blood flow limited.",Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6270295/),[ml] / [kg·min],17.4,123360,DB00470,Dronabinol
,6270295,total (metabolic) blood clearance,"The total (metabolic) blood clearance of THC averaged 17.4 ml/min/kg without CBD and 20.9 ml/min/kg with CBD, and was probably hepatic blood flow limited.",Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6270295/),[ml] / [kg·min],20.9,123361,DB00470,Dronabinol
,6270295,apparent steady-state volume of distribution,"The apparent steady-state volume of distribution averaged 9.86 (with CBD, 10.54) liters/kg.",Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6270295/),[l] / [kg],9.86,123362,DB00470,Dronabinol
,6270295,apparent steady-state volume of distribution,"The apparent steady-state volume of distribution averaged 9.86 (with CBD, 10.54) liters/kg.",Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6270295/),[l] / [kg],10.54,123363,DB00470,Dronabinol
,6270295,renal clearance,"Irrespective of CBD pretreatment, the renal clearance of THC metabolites ranged from 17 ml/min after approximately 1 hr to 1.13 ml/min 3.5 days after dosing with THC.",Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6270295/),[ml] / [min],17,123364,DB00470,Dronabinol
,6270295,renal clearance,"Irrespective of CBD pretreatment, the renal clearance of THC metabolites ranged from 17 ml/min after approximately 1 hr to 1.13 ml/min 3.5 days after dosing with THC.",Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6270295/),[ml] / [min],1.13,123365,DB00470,Dronabinol
,6270295,apparent terminal halflife,The apparent terminal halflife for metabolites averaged 8.2 days.,Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6270295/),d,8.2,123366,DB00470,Dronabinol
,29317112,time for,The predicted time for concentrations to drop <5ng/mL was 49days after administration.,Cannabinoid Disposition After Human Intraperitoneal Use: AnInsight Into Intraperitoneal Pharmacokinetic Properties in Metastatic Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29317112/),d,49,127778,DB00470,Dronabinol
,22411724,plasma AUC (24 h),The metabolic pattern was significantly different after administration of the different forms: the heated extract showed a lower median THC plasma AUC (24 h) than the unheated extract of 2.84 vs.,Heat exposure of Cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22411724/),,2.84,127909,DB00470,Dronabinol
,22411724,later,The later was slightly higher than that of dronabinol (4.58 pmol h/mL).,Heat exposure of Cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22411724/),[h·pM] / [ml],4.58,127910,DB00470,Dronabinol
,6267648,systemic availability,The systemic availability of smoked delta 9-THC was significantly higher for the heavy users (heavy users 23 +/- 16% vs 10 +/- 7% for light users).,Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6267648/),%,23,128732,DB00470,Dronabinol
,6267648,systemic availability,The systemic availability of smoked delta 9-THC was significantly higher for the heavy users (heavy users 23 +/- 16% vs 10 +/- 7% for light users).,Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6267648/),%,10,128733,DB00470,Dronabinol
,25316574,apparent terminal half-life,"Results show that THC has a fast initial and intermediate half-life, while the apparent terminal half-life is long (21.5 h), with a clearance of 38.8 L/h.","Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25316574/),h,21.5,131557,DB00470,Dronabinol
,25316574,clearance,"Results show that THC has a fast initial and intermediate half-life, while the apparent terminal half-life is long (21.5 h), with a clearance of 38.8 L/h.","Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25316574/),[l] / [h],38.8,131558,DB00470,Dronabinol
,16237477,bioavailability,THC bioavailability averages 30%.,Pharmacokinetics of cannabinoids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16237477/),%,30,132223,DB00470,Dronabinol
,16237477,peak plasma level,"With a 3.55% THC cigarette, a peak plasma level of 152±86.3 ng/mL occured approximately 10 min after inhalation.",Pharmacokinetics of cannabinoids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16237477/),[ng] / [ml],152,132224,DB00470,Dronabinol
,16237477,bioavailable,"Oral THC, on the other hand, is only 4% to 12% bioavailable and absorption is highly variable.",Pharmacokinetics of cannabinoids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16237477/),%,4,132225,DB00470,Dronabinol
,16237477,plasma elimination half-life,"Nabilone is well absorbed and the pharmacokinetics, although variable, appear to be linear from oral doses of 1 mg to 4 mg (these doses show a plasma elimination half-life of approximately 2 h).",Pharmacokinetics of cannabinoids. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16237477/),h,2,132226,DB00470,Dronabinol
,28158482,Cmax,"The mean Cmax for THC in whole blood was 1, 3.5 and 3.3 ng/mL for the 10, 25 and 50 mg THC doses, respectively.",Pharmacokinetic Profile of Oral Cannabis in Humans: Blood and Oral Fluid Disposition and Relation to Pharmacodynamic Outcomes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28158482/),[ng] / [ml],1,133753,DB00470,Dronabinol
,28158482,Cmax,"The mean Cmax for THC in whole blood was 1, 3.5 and 3.3 ng/mL for the 10, 25 and 50 mg THC doses, respectively.",Pharmacokinetic Profile of Oral Cannabis in Humans: Blood and Oral Fluid Disposition and Relation to Pharmacodynamic Outcomes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28158482/),[ng] / [ml],3.5,133754,DB00470,Dronabinol
,28158482,Cmax,"The mean Cmax for THC in whole blood was 1, 3.5 and 3.3 ng/mL for the 10, 25 and 50 mg THC doses, respectively.",Pharmacokinetic Profile of Oral Cannabis in Humans: Blood and Oral Fluid Disposition and Relation to Pharmacodynamic Outcomes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28158482/),[ng] / [ml],3.3,133755,DB00470,Dronabinol
,26427296,bioavailability,This increase has important implications not only for the pharmacokinetics but also for the pharmacology of THC The mean bioavailability of THC in smoked cannabis is about 25%.,[Tetrahydrocannabinol pharmacokinetics; new synthetic cannabinoids; road safety and cannabis]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26427296/),%,25,135037,DB00470,Dronabinol
,26427296,peak plasma level,"In a cigarette containing 3.55% of THC, a peak plasma level of about 160 ng/mL occurs approximately 10 min after inhalation.",[Tetrahydrocannabinol pharmacokinetics; new synthetic cannabinoids; road safety and cannabis]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26427296/),[ng] / [ml],160,135038,DB00470,Dronabinol
,6256518,total metabolic clearance,"Development of tolerance was paralleled by pharmacokinetic changes: 1) average total metabolic clearance and the initial apparent volume of distribution increased from 605 to 977 ml/min and from 2.6 to 6.4 liters, respectively; 2) steady-state volume of distribution, averaging 684 liters, was unaltered; 3) the majority of model-dependent pharmacokinetic parameters as well as the time course of total metabolites in plasma were unchanged; 4) the percent dose excreted in urine decreased from 23.2 to 17.5%, but total elimination (urine plus feces) was not significantly changed; and 5) metabolites were rapidly formed (t 1/2 = 2.8-4.4 min), but slowly eliminated (t 1/2 = 49-53 hours) because of extensive protein binding.",Tolerance and disposition of tetrahydrocannabinol in man. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6256518/),[ml] / [min],605 to 977,139001,DB00470,Dronabinol
,6256518,initial apparent volume of distribution,"Development of tolerance was paralleled by pharmacokinetic changes: 1) average total metabolic clearance and the initial apparent volume of distribution increased from 605 to 977 ml/min and from 2.6 to 6.4 liters, respectively; 2) steady-state volume of distribution, averaging 684 liters, was unaltered; 3) the majority of model-dependent pharmacokinetic parameters as well as the time course of total metabolites in plasma were unchanged; 4) the percent dose excreted in urine decreased from 23.2 to 17.5%, but total elimination (urine plus feces) was not significantly changed; and 5) metabolites were rapidly formed (t 1/2 = 2.8-4.4 min), but slowly eliminated (t 1/2 = 49-53 hours) because of extensive protein binding.",Tolerance and disposition of tetrahydrocannabinol in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6256518/),l,2.6 to 6.4,139002,DB00470,Dronabinol
,6256518,steady-state volume of distribution,"Development of tolerance was paralleled by pharmacokinetic changes: 1) average total metabolic clearance and the initial apparent volume of distribution increased from 605 to 977 ml/min and from 2.6 to 6.4 liters, respectively; 2) steady-state volume of distribution, averaging 684 liters, was unaltered; 3) the majority of model-dependent pharmacokinetic parameters as well as the time course of total metabolites in plasma were unchanged; 4) the percent dose excreted in urine decreased from 23.2 to 17.5%, but total elimination (urine plus feces) was not significantly changed; and 5) metabolites were rapidly formed (t 1/2 = 2.8-4.4 min), but slowly eliminated (t 1/2 = 49-53 hours) because of extensive protein binding.",Tolerance and disposition of tetrahydrocannabinol in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6256518/),l,684,139003,DB00470,Dronabinol
,6256518,t 1/2,"Development of tolerance was paralleled by pharmacokinetic changes: 1) average total metabolic clearance and the initial apparent volume of distribution increased from 605 to 977 ml/min and from 2.6 to 6.4 liters, respectively; 2) steady-state volume of distribution, averaging 684 liters, was unaltered; 3) the majority of model-dependent pharmacokinetic parameters as well as the time course of total metabolites in plasma were unchanged; 4) the percent dose excreted in urine decreased from 23.2 to 17.5%, but total elimination (urine plus feces) was not significantly changed; and 5) metabolites were rapidly formed (t 1/2 = 2.8-4.4 min), but slowly eliminated (t 1/2 = 49-53 hours) because of extensive protein binding.",Tolerance and disposition of tetrahydrocannabinol in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6256518/),min,2.8-4.4,139004,DB00470,Dronabinol
,6256518,t 1/2,"Development of tolerance was paralleled by pharmacokinetic changes: 1) average total metabolic clearance and the initial apparent volume of distribution increased from 605 to 977 ml/min and from 2.6 to 6.4 liters, respectively; 2) steady-state volume of distribution, averaging 684 liters, was unaltered; 3) the majority of model-dependent pharmacokinetic parameters as well as the time course of total metabolites in plasma were unchanged; 4) the percent dose excreted in urine decreased from 23.2 to 17.5%, but total elimination (urine plus feces) was not significantly changed; and 5) metabolites were rapidly formed (t 1/2 = 2.8-4.4 min), but slowly eliminated (t 1/2 = 49-53 hours) because of extensive protein binding.",Tolerance and disposition of tetrahydrocannabinol in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6256518/),h,49-53,139005,DB00470,Dronabinol
,6256518,Renal clearance,"Renal clearance values of total metabolites were surprisingly low (maximum of 18-20 ml/min) and decreased with time (approximately 1 ml/min after 4-5 days), indicating the accumulation of highly bound metabolites.",Tolerance and disposition of tetrahydrocannabinol in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6256518/),[ml] / [min],18-20,139006,DB00470,Dronabinol
,6256518,Renal clearance,"Renal clearance values of total metabolites were surprisingly low (maximum of 18-20 ml/min) and decreased with time (approximately 1 ml/min after 4-5 days), indicating the accumulation of highly bound metabolites.",Tolerance and disposition of tetrahydrocannabinol in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6256518/),[ml] / [min],1,139007,DB00470,Dronabinol
less,1323733,Ratios,Ratios for the subsequent 12 days were less than 2.,Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1323733/),,2,140017,DB00470,Dronabinol
,33346629,limit of quantification,"The limit of quantification and limit of detection were 0.26 and 0.86 ng/mL, respectively.",An Ultrafast Ultrahigh-Performance Liquid Chromatography Coupled With Tandem Mass Spectrometry Method for Cannabidiol Monitoring in Pediatric Refractory Epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33346629/),[ng] / [ml],0.26,148976,DB00470,Dronabinol
,33346629,limit of detection,"The limit of quantification and limit of detection were 0.26 and 0.86 ng/mL, respectively.",An Ultrafast Ultrahigh-Performance Liquid Chromatography Coupled With Tandem Mass Spectrometry Method for Cannabidiol Monitoring in Pediatric Refractory Epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33346629/),[ng] / [ml],0.86,148977,DB00470,Dronabinol
,33346629,recovery,"CBD recovery and matrix effects were 83.9 ± 13.9% and 117.4 ± 4.5%, respectively.",An Ultrafast Ultrahigh-Performance Liquid Chromatography Coupled With Tandem Mass Spectrometry Method for Cannabidiol Monitoring in Pediatric Refractory Epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33346629/),%,83.9,148978,DB00470,Dronabinol
,33346629,matrix effects,"CBD recovery and matrix effects were 83.9 ± 13.9% and 117.4 ± 4.5%, respectively.",An Ultrafast Ultrahigh-Performance Liquid Chromatography Coupled With Tandem Mass Spectrometry Method for Cannabidiol Monitoring in Pediatric Refractory Epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33346629/),%,117.4,148979,DB00470,Dronabinol
<,9314087,distribution half-life,"The elimination of dexanabinol was best fitted to a 3-compartment model with a rapid distribution half-life (< 5 min), an intermediate phase half-life of approximately 90 min, and a slow terminal elimination half-life (approximately 9 h).","Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9314087/),min,5,152248,DB00470,Dronabinol
,9314087,intermediate phase half-life,"The elimination of dexanabinol was best fitted to a 3-compartment model with a rapid distribution half-life (< 5 min), an intermediate phase half-life of approximately 90 min, and a slow terminal elimination half-life (approximately 9 h).","Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9314087/),min,90,152249,DB00470,Dronabinol
,9314087,terminal elimination half-life,"The elimination of dexanabinol was best fitted to a 3-compartment model with a rapid distribution half-life (< 5 min), an intermediate phase half-life of approximately 90 min, and a slow terminal elimination half-life (approximately 9 h).","Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9314087/),h,9,152250,DB00470,Dronabinol
,9314087,plasma clearance,"The plasma clearance of the drug was high (1,700 ml/min) and the volume of distribution approximately 15 l/kg.","Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9314087/),[ml] / [min],"1,700",152251,DB00470,Dronabinol
,9314087,volume of distribution,"The plasma clearance of the drug was high (1,700 ml/min) and the volume of distribution approximately 15 l/kg.","Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9314087/),[l] / [kg],15,152252,DB00470,Dronabinol
,30077950,total run time,"The total run time was 6 min, and separation was achieved using isocratic elution at a flow rate of 1 mL/min using a 10:90 (aqueous: organic) ratio.","Simultaneous quantification of cannabinoids tetrahydrocannabinol, cannabidiol and CB1 receptor antagonist in rat plasma: An application to characterize pharmacokinetics after passive cannabis smoke inhalation and co-administration of rimonabant. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30077950/),min,6,165960,DB00470,Dronabinol
,30077950,flow rate,"The total run time was 6 min, and separation was achieved using isocratic elution at a flow rate of 1 mL/min using a 10:90 (aqueous: organic) ratio.","Simultaneous quantification of cannabinoids tetrahydrocannabinol, cannabidiol and CB1 receptor antagonist in rat plasma: An application to characterize pharmacokinetics after passive cannabis smoke inhalation and co-administration of rimonabant. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30077950/),[ml] / [min],1,165961,DB00470,Dronabinol
,30077950,terminal half-life,Maximum concentration (Cmax) for THC was observed immediately after rats were removed from the exposure chamber (10 min post completion) which declined with a terminal half-life of 3.7 h and clearance was calculated to be 1.1 (L/h).,"Simultaneous quantification of cannabinoids tetrahydrocannabinol, cannabidiol and CB1 receptor antagonist in rat plasma: An application to characterize pharmacokinetics after passive cannabis smoke inhalation and co-administration of rimonabant. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30077950/),h,3.7,165962,DB00470,Dronabinol
,30077950,clearance,Maximum concentration (Cmax) for THC was observed immediately after rats were removed from the exposure chamber (10 min post completion) which declined with a terminal half-life of 3.7 h and clearance was calculated to be 1.1 (L/h).,"Simultaneous quantification of cannabinoids tetrahydrocannabinol, cannabidiol and CB1 receptor antagonist in rat plasma: An application to characterize pharmacokinetics after passive cannabis smoke inhalation and co-administration of rimonabant. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30077950/),[l] / [h],1.1,165963,DB00470,Dronabinol
,30077950,terminal half-life,Rimonabant (i.p) at a dose of 3 mg/kg was rapidly absorbed and maximum concentration (Cmax) was seen at 11 min which declined with a terminal half-life of 5.4 h and clearance was calculated to be 2.0 (L/h).,"Simultaneous quantification of cannabinoids tetrahydrocannabinol, cannabidiol and CB1 receptor antagonist in rat plasma: An application to characterize pharmacokinetics after passive cannabis smoke inhalation and co-administration of rimonabant. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30077950/),h,5.4,165964,DB00470,Dronabinol
,30077950,clearance,Rimonabant (i.p) at a dose of 3 mg/kg was rapidly absorbed and maximum concentration (Cmax) was seen at 11 min which declined with a terminal half-life of 5.4 h and clearance was calculated to be 2.0 (L/h).,"Simultaneous quantification of cannabinoids tetrahydrocannabinol, cannabidiol and CB1 receptor antagonist in rat plasma: An application to characterize pharmacokinetics after passive cannabis smoke inhalation and co-administration of rimonabant. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30077950/),[l] / [h],2.0,165965,DB00470,Dronabinol
,30077950,AUCinf,Exposure AUCinf (h* μg/L) for THC and rimonabant were 13.9 and 457.6 respectively.,"Simultaneous quantification of cannabinoids tetrahydrocannabinol, cannabidiol and CB1 receptor antagonist in rat plasma: An application to characterize pharmacokinetics after passive cannabis smoke inhalation and co-administration of rimonabant. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30077950/),[h·μg] / [l],13.9,165966,DB00470,Dronabinol
,30077950,AUCinf,Exposure AUCinf (h* μg/L) for THC and rimonabant were 13.9 and 457.6 respectively.,"Simultaneous quantification of cannabinoids tetrahydrocannabinol, cannabidiol and CB1 receptor antagonist in rat plasma: An application to characterize pharmacokinetics after passive cannabis smoke inhalation and co-administration of rimonabant. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30077950/),[h·μg] / [l],457.6,165967,DB00470,Dronabinol
,2558889,plasma elimination half-life,The pharmacokinetic behavior was consistent with a multicompartment model with a mean plasma elimination half-life of delta 1-THC of 4.3 days when concentrations were followed for 10-15 days after smoking.,Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2558889/),d,4.3,166484,DB00470,Dronabinol
,2558889,half-lives,"In the two subjects with detectable plasma levels during 4 weeks, half-lives of 9.6 and 12.6 days was obtained.",Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2558889/),d,9.6,166485,DB00470,Dronabinol
,2558889,half-lives,"In the two subjects with detectable plasma levels during 4 weeks, half-lives of 9.6 and 12.6 days was obtained.",Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2558889/),d,12.6,166486,DB00470,Dronabinol
,872500,half-life,"The absorbed drug disappeared from plasma rather rapidly (half-life, approximately 2 hr), evidently due to extensive tissue distribution and rapid metabolism.","Physiologic disposition of nabilone, a cannabinol derivative, in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/872500/),h,2,169231,DB00470,Dronabinol
exceeds,872500,half-life of total radioactivity,The metabolites of nabilone persist in plasma for extended periods (half-life of total radioactivity exceeds 20 hr).,"Physiologic disposition of nabilone, a cannabinol derivative, in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/872500/),h,20,169232,DB00470,Dronabinol
,27113702,Central volumes of distribution,"Central volumes of distribution were estimated at 0.29L/kg, 0.20L/kg, and 0.67L/kg for THC, JWH-210, and RCS-4, respectively.",Pharmacokinetics of (synthetic) cannabinoids in pigs and their relevance for clinical and forensic toxicology. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27113702/),[l] / [kg],0.29,170478,DB00470,Dronabinol
,27113702,Central volumes of distribution,"Central volumes of distribution were estimated at 0.29L/kg, 0.20L/kg, and 0.67L/kg for THC, JWH-210, and RCS-4, respectively.",Pharmacokinetics of (synthetic) cannabinoids in pigs and their relevance for clinical and forensic toxicology. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27113702/),[l] / [kg],0.20,170479,DB00470,Dronabinol
,27113702,Central volumes of distribution,"Central volumes of distribution were estimated at 0.29L/kg, 0.20L/kg, and 0.67L/kg for THC, JWH-210, and RCS-4, respectively.",Pharmacokinetics of (synthetic) cannabinoids in pigs and their relevance for clinical and forensic toxicology. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27113702/),[l] / [kg],0.67,170480,DB00470,Dronabinol
,27113702,Clearances,"Clearances were 0.042L/min/kg, 0.048L/min/kg, and 0.093L/min/kg for THC, JWH-210, and RCS-4, respectively.",Pharmacokinetics of (synthetic) cannabinoids in pigs and their relevance for clinical and forensic toxicology. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27113702/),[l] / [kg·min],0.042,170481,DB00470,Dronabinol
,27113702,Clearances,"Clearances were 0.042L/min/kg, 0.048L/min/kg, and 0.093L/min/kg for THC, JWH-210, and RCS-4, respectively.",Pharmacokinetics of (synthetic) cannabinoids in pigs and their relevance for clinical and forensic toxicology. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27113702/),[l] / [kg·min],0.048,170482,DB00470,Dronabinol
,27113702,Clearances,"Clearances were 0.042L/min/kg, 0.048L/min/kg, and 0.093L/min/kg for THC, JWH-210, and RCS-4, respectively.",Pharmacokinetics of (synthetic) cannabinoids in pigs and their relevance for clinical and forensic toxicology. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27113702/),[l] / [kg·min],0.093,170483,DB00470,Dronabinol
,24956859,limit of detection (LOD),"The limit of detection (LOD) was 0.7 microg x L(-1), respectively.",[Pharmacokinetics and relative bioavailability of THC and THC-solid dispersion orally to mice at single dose]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24956859/),[μg] / [l],0.7,171965,DB00470,Dronabinol
above,24956859,extraction recoveries,"The average extraction recoveries for THC was above 75%, The methodology recoveries were between 79% and 108%.",[Pharmacokinetics and relative bioavailability of THC and THC-solid dispersion orally to mice at single dose]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24956859/),%,75,171966,DB00470,Dronabinol
,24956859,recoveries,"The average extraction recoveries for THC was above 75%, The methodology recoveries were between 79% and 108%.",[Pharmacokinetics and relative bioavailability of THC and THC-solid dispersion orally to mice at single dose]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24956859/),%,79,171967,DB00470,Dronabinol
,24956859,recoveries,"The average extraction recoveries for THC was above 75%, The methodology recoveries were between 79% and 108%.",[Pharmacokinetics and relative bioavailability of THC and THC-solid dispersion orally to mice at single dose]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24956859/),%,108,171968,DB00470,Dronabinol
,24956859,T(max),"Pharmacokinetic parameters of THC and THC-solid dispersion orally to mice shows as fllows: T(max), were 60 and 15 min, AUC(0-t) were 44 500.43 and 57 497.81 mg x L(-1) x min, AUC(0-infinity) were 51 226.00 and 68 031.48 mg x L(-1) x min, MRT(0-infinity) were 596.915 6, 661.747 7 min, CL(z)/F were 0.007 809 and 0.005 88 L x min(-1) x kg(-1).",[Pharmacokinetics and relative bioavailability of THC and THC-solid dispersion orally to mice at single dose]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24956859/),min,60,171969,DB00470,Dronabinol
,24956859,T(max),"Pharmacokinetic parameters of THC and THC-solid dispersion orally to mice shows as fllows: T(max), were 60 and 15 min, AUC(0-t) were 44 500.43 and 57 497.81 mg x L(-1) x min, AUC(0-infinity) were 51 226.00 and 68 031.48 mg x L(-1) x min, MRT(0-infinity) were 596.915 6, 661.747 7 min, CL(z)/F were 0.007 809 and 0.005 88 L x min(-1) x kg(-1).",[Pharmacokinetics and relative bioavailability of THC and THC-solid dispersion orally to mice at single dose]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24956859/),min,15,171970,DB00470,Dronabinol
,24956859,AUC(0-t),"Pharmacokinetic parameters of THC and THC-solid dispersion orally to mice shows as fllows: T(max), were 60 and 15 min, AUC(0-t) were 44 500.43 and 57 497.81 mg x L(-1) x min, AUC(0-infinity) were 51 226.00 and 68 031.48 mg x L(-1) x min, MRT(0-infinity) were 596.915 6, 661.747 7 min, CL(z)/F were 0.007 809 and 0.005 88 L x min(-1) x kg(-1).",[Pharmacokinetics and relative bioavailability of THC and THC-solid dispersion orally to mice at single dose]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24956859/),[mg·min] / [l],44 500.43,171971,DB00470,Dronabinol
,24956859,AUC(0-t),"Pharmacokinetic parameters of THC and THC-solid dispersion orally to mice shows as fllows: T(max), were 60 and 15 min, AUC(0-t) were 44 500.43 and 57 497.81 mg x L(-1) x min, AUC(0-infinity) were 51 226.00 and 68 031.48 mg x L(-1) x min, MRT(0-infinity) were 596.915 6, 661.747 7 min, CL(z)/F were 0.007 809 and 0.005 88 L x min(-1) x kg(-1).",[Pharmacokinetics and relative bioavailability of THC and THC-solid dispersion orally to mice at single dose]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24956859/),[mg·min] / [l],57 497.81,171972,DB00470,Dronabinol
,24956859,AUC(0-infinity),"Pharmacokinetic parameters of THC and THC-solid dispersion orally to mice shows as fllows: T(max), were 60 and 15 min, AUC(0-t) were 44 500.43 and 57 497.81 mg x L(-1) x min, AUC(0-infinity) were 51 226.00 and 68 031.48 mg x L(-1) x min, MRT(0-infinity) were 596.915 6, 661.747 7 min, CL(z)/F were 0.007 809 and 0.005 88 L x min(-1) x kg(-1).",[Pharmacokinetics and relative bioavailability of THC and THC-solid dispersion orally to mice at single dose]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24956859/),[mg·min] / [l],51 226.00,171973,DB00470,Dronabinol
,24956859,AUC(0-infinity),"Pharmacokinetic parameters of THC and THC-solid dispersion orally to mice shows as fllows: T(max), were 60 and 15 min, AUC(0-t) were 44 500.43 and 57 497.81 mg x L(-1) x min, AUC(0-infinity) were 51 226.00 and 68 031.48 mg x L(-1) x min, MRT(0-infinity) were 596.915 6, 661.747 7 min, CL(z)/F were 0.007 809 and 0.005 88 L x min(-1) x kg(-1).",[Pharmacokinetics and relative bioavailability of THC and THC-solid dispersion orally to mice at single dose]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24956859/),[mg·min] / [l],68 031.48,171974,DB00470,Dronabinol
,24956859,MRT(0-infinity),"Pharmacokinetic parameters of THC and THC-solid dispersion orally to mice shows as fllows: T(max), were 60 and 15 min, AUC(0-t) were 44 500.43 and 57 497.81 mg x L(-1) x min, AUC(0-infinity) were 51 226.00 and 68 031.48 mg x L(-1) x min, MRT(0-infinity) were 596.915 6, 661.747 7 min, CL(z)/F were 0.007 809 and 0.005 88 L x min(-1) x kg(-1).",[Pharmacokinetics and relative bioavailability of THC and THC-solid dispersion orally to mice at single dose]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24956859/),6,596.915,171975,DB00470,Dronabinol
,24956859,MRT(0-infinity),"Pharmacokinetic parameters of THC and THC-solid dispersion orally to mice shows as fllows: T(max), were 60 and 15 min, AUC(0-t) were 44 500.43 and 57 497.81 mg x L(-1) x min, AUC(0-infinity) were 51 226.00 and 68 031.48 mg x L(-1) x min, MRT(0-infinity) were 596.915 6, 661.747 7 min, CL(z)/F were 0.007 809 and 0.005 88 L x min(-1) x kg(-1).",[Pharmacokinetics and relative bioavailability of THC and THC-solid dispersion orally to mice at single dose]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24956859/),min,661.747 7,171976,DB00470,Dronabinol
,24956859,CL(z)/F,"Pharmacokinetic parameters of THC and THC-solid dispersion orally to mice shows as fllows: T(max), were 60 and 15 min, AUC(0-t) were 44 500.43 and 57 497.81 mg x L(-1) x min, AUC(0-infinity) were 51 226.00 and 68 031.48 mg x L(-1) x min, MRT(0-infinity) were 596.915 6, 661.747 7 min, CL(z)/F were 0.007 809 and 0.005 88 L x min(-1) x kg(-1).",[Pharmacokinetics and relative bioavailability of THC and THC-solid dispersion orally to mice at single dose]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24956859/),[l] / [kg·min],0.007 809,171977,DB00470,Dronabinol
,24956859,CL(z)/F,"Pharmacokinetic parameters of THC and THC-solid dispersion orally to mice shows as fllows: T(max), were 60 and 15 min, AUC(0-t) were 44 500.43 and 57 497.81 mg x L(-1) x min, AUC(0-infinity) were 51 226.00 and 68 031.48 mg x L(-1) x min, MRT(0-infinity) were 596.915 6, 661.747 7 min, CL(z)/F were 0.007 809 and 0.005 88 L x min(-1) x kg(-1).",[Pharmacokinetics and relative bioavailability of THC and THC-solid dispersion orally to mice at single dose]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24956859/),[l] / [kg·min],0.005 88,171978,DB00470,Dronabinol
,32504461,absolute bioavailability,"Although detailed studies have not been published, the available data suggest that the absolute bioavailability of CBD after oral dosing under fasting conditions is approximately 6%, and increases fourfold when the medication is co-administered with a high-fat meal.","Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32504461/),%,6,185033,DB00470,Dronabinol
,32504461,absolute oral bioavailability,"Based on measurements of CBD plasma exposure after oral dosing and a 6% absolute oral bioavailability estimate, the actual clearance of CBD in adults can be inferred to be in the order of 67 L/h, which is similar to the value of 74 ± 14 L/h (mean ± standard deviation) determined after intravenous injection of a 20-mg dose of deuterium-labeled CBD in five healthy subjects.","Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32504461/),%,6,185034,DB00470,Dronabinol
,32504461,absolute oral bioavailability,"Based on measurements of CBD plasma exposure after oral dosing and a 6% absolute oral bioavailability estimate, the actual clearance of CBD in adults can be inferred to be in the order of 67 L/h, which is similar to the value of 74 ± 14 L/h (mean ± standard deviation) determined after intravenous injection of a 20-mg dose of deuterium-labeled CBD in five healthy subjects.","Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32504461/),[l] / [h],67,185035,DB00470,Dronabinol
,32504461,absolute oral bioavailability,"Based on measurements of CBD plasma exposure after oral dosing and a 6% absolute oral bioavailability estimate, the actual clearance of CBD in adults can be inferred to be in the order of 67 L/h, which is similar to the value of 74 ± 14 L/h (mean ± standard deviation) determined after intravenous injection of a 20-mg dose of deuterium-labeled CBD in five healthy subjects.","Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32504461/),[l] / [h],74,185036,DB00470,Dronabinol
,32504461,clearance,"Based on measurements of CBD plasma exposure after oral dosing and a 6% absolute oral bioavailability estimate, the actual clearance of CBD in adults can be inferred to be in the order of 67 L/h, which is similar to the value of 74 ± 14 L/h (mean ± standard deviation) determined after intravenous injection of a 20-mg dose of deuterium-labeled CBD in five healthy subjects.","Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32504461/),[l] / [h],67,185037,DB00470,Dronabinol
,32504461,clearance,"Based on measurements of CBD plasma exposure after oral dosing and a 6% absolute oral bioavailability estimate, the actual clearance of CBD in adults can be inferred to be in the order of 67 L/h, which is similar to the value of 74 ± 14 L/h (mean ± standard deviation) determined after intravenous injection of a 20-mg dose of deuterium-labeled CBD in five healthy subjects.","Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32504461/),[l] / [h],74,185038,DB00470,Dronabinol
,32504461,blood-to-plasma ratio,"Assuming that the CBD blood-to-plasma ratio is about 1, as in the case of tetrahydrocannabinol (THC), and that CBD metabolism takes place virtually entirely in the liver, it can be estimated that about 70 to 75% of an orally absorbed dose of CBD can be removed by hepatic metabolism before reaching the systemic circulation, and additionally CBD gastrointestinal absorption is incomplete.","Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32504461/),,1,185039,DB00470,Dronabinol
,19833841,peak plasma free THC,"Mean peak plasma free THC, 11-OH-THC, and THCCOOH concentrations were 3.8 (0.5), 3.0 (0.7), and 196.9 (39.9) mug/L, respectively, 22.5 h after the last dose.","Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19833841/),[μg] / [l],3.8,185409,DB00470,Dronabinol
,1664466,bioavailability,The calculated bioavailability of delta 9-THC from this formulation was found to be 13.5%.,Rectal bioavailability of delta-9-tetrahydrocannabinol from the hemisuccinate ester in monkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1664466/),%,13.5,188904,DB00470,Dronabinol
,1664466,mean residence time (MRT),"Non-compartmental analysis of the plasma concentration data using statistical moments showed the mean residence time (MRT) for delta 9-THC in the body to be 3 h following iv administration of delta 9-THC or its hemisuccinate ester (3.4 and 2.7 h, respectively), as compared with 5.8 h following rectal administration of the delta 9-THC hemisuccinate.",Rectal bioavailability of delta-9-tetrahydrocannabinol from the hemisuccinate ester in monkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1664466/),h,3,188905,DB00470,Dronabinol
,1664466,mean residence time (MRT),"Non-compartmental analysis of the plasma concentration data using statistical moments showed the mean residence time (MRT) for delta 9-THC in the body to be 3 h following iv administration of delta 9-THC or its hemisuccinate ester (3.4 and 2.7 h, respectively), as compared with 5.8 h following rectal administration of the delta 9-THC hemisuccinate.",Rectal bioavailability of delta-9-tetrahydrocannabinol from the hemisuccinate ester in monkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1664466/),h,3.4,188906,DB00470,Dronabinol
,1664466,mean residence time (MRT),"Non-compartmental analysis of the plasma concentration data using statistical moments showed the mean residence time (MRT) for delta 9-THC in the body to be 3 h following iv administration of delta 9-THC or its hemisuccinate ester (3.4 and 2.7 h, respectively), as compared with 5.8 h following rectal administration of the delta 9-THC hemisuccinate.",Rectal bioavailability of delta-9-tetrahydrocannabinol from the hemisuccinate ester in monkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1664466/),h,2.7,188907,DB00470,Dronabinol
,1664466,mean residence time (MRT),"Non-compartmental analysis of the plasma concentration data using statistical moments showed the mean residence time (MRT) for delta 9-THC in the body to be 3 h following iv administration of delta 9-THC or its hemisuccinate ester (3.4 and 2.7 h, respectively), as compared with 5.8 h following rectal administration of the delta 9-THC hemisuccinate.",Rectal bioavailability of delta-9-tetrahydrocannabinol from the hemisuccinate ester in monkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1664466/),h,5.8,188908,DB00470,Dronabinol
,6268351,sensitivity of detection,The sensitivity of detection (4 ng/mL) is compatible with cannabinoid kinetics.,Detection and quantitation of cannabinoids in biological fluids: specificity and kinetics after smoking. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6268351/),[ng] / [ml],4,189265,DB00470,Dronabinol
,6271823,terminal-phase (beta-phase) plasma half-life,"Initial pharmacokinetic analyses of the data show that the mean terminal-phase (beta-phase) plasma half-life after intravenous administration of THC was about 30 hours; after oral administration, it was 23 hours.",The metabolism of delta 9-tetrahydrocannabinol and related cannabinoids in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6271823/),h,30,189464,DB00470,Dronabinol
,6271823,terminal-phase (beta-phase) plasma half-life,"Initial pharmacokinetic analyses of the data show that the mean terminal-phase (beta-phase) plasma half-life after intravenous administration of THC was about 30 hours; after oral administration, it was 23 hours.",The metabolism of delta 9-tetrahydrocannabinol and related cannabinoids in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6271823/),h,23,189465,DB00470,Dronabinol
,15955678,F,The absolute bioavailability (F) of THC decreased in the following order: sublingual THC/RM-beta-CD solution (F = 12.1+/-1.4%; mean+/-S.D.; n = 4) > oral THC/RM-beta-CD solution (F = 4.0+/-6.0%) > or = sublingual ethanolic THC solution (F = 3.8+/-2.8%) > oral ethanolic THC solution (F = 1.3+/-1.4%).,Effects of RM-beta-CD on sublingual bioavailability of Delta9-tetrahydrocannabinol in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15955678/),%,12.1,189647,DB00470,Dronabinol
,15955678,F,The absolute bioavailability (F) of THC decreased in the following order: sublingual THC/RM-beta-CD solution (F = 12.1+/-1.4%; mean+/-S.D.; n = 4) > oral THC/RM-beta-CD solution (F = 4.0+/-6.0%) > or = sublingual ethanolic THC solution (F = 3.8+/-2.8%) > oral ethanolic THC solution (F = 1.3+/-1.4%).,Effects of RM-beta-CD on sublingual bioavailability of Delta9-tetrahydrocannabinol in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15955678/),%,4.0,189648,DB00470,Dronabinol
,15955678,F,The absolute bioavailability (F) of THC decreased in the following order: sublingual THC/RM-beta-CD solution (F = 12.1+/-1.4%; mean+/-S.D.; n = 4) > oral THC/RM-beta-CD solution (F = 4.0+/-6.0%) > or = sublingual ethanolic THC solution (F = 3.8+/-2.8%) > oral ethanolic THC solution (F = 1.3+/-1.4%).,Effects of RM-beta-CD on sublingual bioavailability of Delta9-tetrahydrocannabinol in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15955678/),%,3.8,189649,DB00470,Dronabinol
,15955678,F,The absolute bioavailability (F) of THC decreased in the following order: sublingual THC/RM-beta-CD solution (F = 12.1+/-1.4%; mean+/-S.D.; n = 4) > oral THC/RM-beta-CD solution (F = 4.0+/-6.0%) > or = sublingual ethanolic THC solution (F = 3.8+/-2.8%) > oral ethanolic THC solution (F = 1.3+/-1.4%).,Effects of RM-beta-CD on sublingual bioavailability of Delta9-tetrahydrocannabinol in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15955678/),%,1.3,189650,DB00470,Dronabinol
,28167229,k10,"The mean values (%Relative Standard Error (RSE)) for k10, k12, k21, k23, k32 and V1 were 0.408h-1 (48.8%), 4.070h-1 (21.4%), 0.022h-1 (27.0%), 1.070h-1 (14.3%), 1.060h-1 (16.7%) and 19.10L (39.7%), respectively.",Population pharmacokinetics model of THC used by pulmonary route in occasional cannabis smokers. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28167229/),1/[h],0.408,190939,DB00470,Dronabinol
,28167229,V1,"The mean values (%Relative Standard Error (RSE)) for k10, k12, k21, k23, k32 and V1 were 0.408h-1 (48.8%), 4.070h-1 (21.4%), 0.022h-1 (27.0%), 1.070h-1 (14.3%), 1.060h-1 (16.7%) and 19.10L (39.7%), respectively.",Population pharmacokinetics model of THC used by pulmonary route in occasional cannabis smokers. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28167229/),1/[h],1.070,190940,DB00470,Dronabinol
,28167229,V1,"The mean values (%Relative Standard Error (RSE)) for k10, k12, k21, k23, k32 and V1 were 0.408h-1 (48.8%), 4.070h-1 (21.4%), 0.022h-1 (27.0%), 1.070h-1 (14.3%), 1.060h-1 (16.7%) and 19.10L (39.7%), respectively.",Population pharmacokinetics model of THC used by pulmonary route in occasional cannabis smokers. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28167229/),1/[h],1.060,190941,DB00470,Dronabinol
,28167229,V1,"The mean values (%Relative Standard Error (RSE)) for k10, k12, k21, k23, k32 and V1 were 0.408h-1 (48.8%), 4.070h-1 (21.4%), 0.022h-1 (27.0%), 1.070h-1 (14.3%), 1.060h-1 (16.7%) and 19.10L (39.7%), respectively.",Population pharmacokinetics model of THC used by pulmonary route in occasional cannabis smokers. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28167229/),l,19.10,190942,DB00470,Dronabinol
,31111749,Peak plasma concentrations,"Peak plasma concentrations (0.8 to 3.6 ng/ml) in most patients were achieved within 2 hours, while acute phase elimination half-life ranged from 1 to 5 hours.",Disposition of oral delta-9 tetrahydrocannabinol (THC) in children receiving cannabis extracts for epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31111749/),[ng] / [ml],0.8 to 3.6,194667,DB00470,Dronabinol
,31111749,acute phase elimination half-life,"Peak plasma concentrations (0.8 to 3.6 ng/ml) in most patients were achieved within 2 hours, while acute phase elimination half-life ranged from 1 to 5 hours.",Disposition of oral delta-9 tetrahydrocannabinol (THC) in children receiving cannabis extracts for epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31111749/),h,1 to 5,194668,DB00470,Dronabinol
,31111749,time to peak plasma concentrations,"Conclusion: In pediatric patients receiving oral THC cannabis extracts, mean time to peak plasma concentrations was 2-7 hours, while mean acute phase elimination half-life was 4.0 hours.",Disposition of oral delta-9 tetrahydrocannabinol (THC) in children receiving cannabis extracts for epilepsy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31111749/),h,2-7,194669,DB00470,Dronabinol
,31111749,acute phase elimination half-life,"Conclusion: In pediatric patients receiving oral THC cannabis extracts, mean time to peak plasma concentrations was 2-7 hours, while mean acute phase elimination half-life was 4.0 hours.",Disposition of oral delta-9 tetrahydrocannabinol (THC) in children receiving cannabis extracts for epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31111749/),h,4.0,194670,DB00470,Dronabinol
,17579974,Highest concentrations,"Highest concentrations in serum were 47.8 +/- 35.0 and 79.1 +/- 42.5 microg/L at the end of smoking (low and high dose, respectively) and decreased to less than 1 microg/L during 6 h with elimination half-lives of 1.4 +/- 0.1 h calculated from 1 to 6 h, which is shorter than reported previously.",Pharmacokinetic properties of delta9-tetrahydrocannabinol in serum and oral fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579974/),[μg] / [l],47.8,194782,DB00470,Dronabinol
,17579974,Highest concentrations,"Highest concentrations in serum were 47.8 +/- 35.0 and 79.1 +/- 42.5 microg/L at the end of smoking (low and high dose, respectively) and decreased to less than 1 microg/L during 6 h with elimination half-lives of 1.4 +/- 0.1 h calculated from 1 to 6 h, which is shorter than reported previously.",Pharmacokinetic properties of delta9-tetrahydrocannabinol in serum and oral fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579974/),[μg] / [l],79.1,194783,DB00470,Dronabinol
,17579974,elimination half-lives,"Highest concentrations in serum were 47.8 +/- 35.0 and 79.1 +/- 42.5 microg/L at the end of smoking (low and high dose, respectively) and decreased to less than 1 microg/L during 6 h with elimination half-lives of 1.4 +/- 0.1 h calculated from 1 to 6 h, which is shorter than reported previously.",Pharmacokinetic properties of delta9-tetrahydrocannabinol in serum and oral fluid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579974/),h,1.4,194784,DB00470,Dronabinol
,17579974,elimination half-lives,The elimination half-lives of THC-OH (2.0 +/- 0.3 h) and THCA (3.4 +/- 0.9 h) were significantly higher.,Pharmacokinetic properties of delta9-tetrahydrocannabinol in serum and oral fluid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579974/),h,2.0,194785,DB00470,Dronabinol
,17579974,elimination half-lives,The elimination half-lives of THC-OH (2.0 +/- 0.3 h) and THCA (3.4 +/- 0.9 h) were significantly higher.,Pharmacokinetic properties of delta9-tetrahydrocannabinol in serum and oral fluid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579974/),h,3.4,194786,DB00470,Dronabinol
,17579974,elimination half-lives,"The THC concentrations in oral fluid were highest with 900 +/- 589 and 1041 +/- 652 microg/L (low and high dose, respectively) in the first sample collected at 0.25 h and decreased to 18 +/- 12 microg/L over 6 h with elimination half-lives of 1.5 +/- 0.6 h.",Pharmacokinetic properties of delta9-tetrahydrocannabinol in serum and oral fluid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579974/),h,1.5,194787,DB00470,Dronabinol
,17579974,Oral fluid/serum ratios,"Oral fluid/serum ratios were 46 +/- 27 and 36 +/- 20 (low and high dose, respectively), which are higher than previously reported and might be based on sample collection and/or analytical issues.",Pharmacokinetic properties of delta9-tetrahydrocannabinol in serum and oral fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579974/),,46,194788,DB00470,Dronabinol
,17579974,Oral fluid/serum ratios,"Oral fluid/serum ratios were 46 +/- 27 and 36 +/- 20 (low and high dose, respectively), which are higher than previously reported and might be based on sample collection and/or analytical issues.",Pharmacokinetic properties of delta9-tetrahydrocannabinol in serum and oral fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579974/),,36,194789,DB00470,Dronabinol
,845807,apparent volume of distribution of the central compartment,"The mean apparent volume of distribution of the central compartment referenced to total drug concentration in the plasma was 1.31 +/- 0.07 liters, approximately the plasma volume, due to the high protein binding of 97%.",Pharmacokinetics of delta9-tetrahydrocannabinol in dogs. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/845807/),l,1.31,194818,DB00470,Dronabinol
,845807,protein,"The mean apparent volume of distribution of the central compartment referenced to total drug concentration in the plasma was 1.31 +/- 0.07 liters, approximately the plasma volume, due to the high protein binding of 97%.",Pharmacokinetics of delta9-tetrahydrocannabinol in dogs. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/845807/),%,97,194819,DB00470,Dronabinol
,845807,metabolic clearance of drug,"The mean metabolic clearance of drug in the plasma was 124 +/- 3.8 ml/min, half of the hepatic plasma flow, but was 4131 +/- 690 ml/min referenced to unbound drug concentration in the plasma, 16.5 times the hepatic plasma flow, indicating that net metabolism of both bound and unbound drug occurs.",Pharmacokinetics of delta9-tetrahydrocannabinol in dogs. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/845807/),[ml] / [min],124,194820,DB00470,Dronabinol
,845807,metabolic clearance of drug,"The mean metabolic clearance of drug in the plasma was 124 +/- 3.8 ml/min, half of the hepatic plasma flow, but was 4131 +/- 690 ml/min referenced to unbound drug concentration in the plasma, 16.5 times the hepatic plasma flow, indicating that net metabolism of both bound and unbound drug occurs.",Pharmacokinetics of delta9-tetrahydrocannabinol in dogs. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/845807/),[ml] / [min],4131,194821,DB00470,Dronabinol
,845807,apparent half-life,The apparent half-life of the metabolic process was 6.9 +/- 0.3 min.,Pharmacokinetics of delta9-tetrahydrocannabinol in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/845807/),min,6.9,194822,DB00470,Dronabinol
,845807,apparent overall volume,"The terminal half-life of delta9-tetrahydrocannabinol in the pseudo-steady state after equilibration in an apparent overall volume of distribtuion of 2170 +/- 555 liters referenced to total plasma concentration was 8.2 +/- 0.23 days, based on the consistency of all pharmacokinetic data.",Pharmacokinetics of delta9-tetrahydrocannabinol in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/845807/),l,2170,194823,DB00470,Dronabinol
,845807,apparent overall volume,"The terminal half-life of delta9-tetrahydrocannabinol in the pseudo-steady state after equilibration in an apparent overall volume of distribtuion of 2170 +/- 555 liters referenced to total plasma concentration was 8.2 +/- 0.23 days, based on the consistency of all pharmacokinetic data.",Pharmacokinetics of delta9-tetrahydrocannabinol in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/845807/),d,8.2,194824,DB00470,Dronabinol
,845807,total,"The terminal half-life of delta9-tetrahydrocannabinol in the pseudo-steady state after equilibration in an apparent overall volume of distribtuion of 2170 +/- 555 liters referenced to total plasma concentration was 8.2 +/- 0.23 days, based on the consistency of all pharmacokinetic data.",Pharmacokinetics of delta9-tetrahydrocannabinol in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/845807/),d,8.2,194825,DB00470,Dronabinol
,845807,terminal half-life,"The best estimate of the terminal half-life, based only on the 7000 min that plasma levels could be monitored with the existing analytical sensitivity, was 1.24 days.",Pharmacokinetics of delta9-tetrahydrocannabinol in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/845807/),d,1.24,194826,DB00470,Dronabinol
,845807,apparent overall volume of distribution,Intravenously administered radiolabeled metabolites were totally and rapidly eliminated in both bile and urine; 88% of the dose in 300 min with an apparent overall volume of distribution of 6 liters.,Pharmacokinetics of delta9-tetrahydrocannabinol in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/845807/),l,6,194827,DB00470,Dronabinol
,22594565,E(max),"An E(max-model) was successfully fitted to individual heart rate, with a THC-OH plasma concentration of 3.2 x 10(-4) μmol/L for EC(50) and an E(max) of 93 bpm for heart rate.",Single-dose pharmacokinetics and tolerability of oral delta-9- tetrahydrocannabinol in patients with amyotrophic lateral sclerosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22594565/),bpm,93,197812,DB00470,Dronabinol
,21836075,observed maximum concentrations (C(max)),"Median whole blood (plasma) observed maximum concentrations (C(max)) were 50 (76), 6.4 (10), 41 (67), 1.3 (2.0), 2.4 (3.6), 89 (190), and 0.7 (1.4) μg/L 0.25 h after starting smoking for THC, 11-OH- THC, THCCOOH, CBD, CBN, and THCCOOH-glucuronide, respectively, and 0.5 h for THC-glucuronide.",Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21836075/),[μg] / [l],50,197881,DB00470,Dronabinol
,21836075,observed maximum concentrations (C(max)),"Median whole blood (plasma) observed maximum concentrations (C(max)) were 50 (76), 6.4 (10), 41 (67), 1.3 (2.0), 2.4 (3.6), 89 (190), and 0.7 (1.4) μg/L 0.25 h after starting smoking for THC, 11-OH- THC, THCCOOH, CBD, CBN, and THCCOOH-glucuronide, respectively, and 0.5 h for THC-glucuronide.",Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21836075/),[μg] / [l],6.4,197882,DB00470,Dronabinol
,21836075,observed maximum concentrations (C(max)),"Median whole blood (plasma) observed maximum concentrations (C(max)) were 50 (76), 6.4 (10), 41 (67), 1.3 (2.0), 2.4 (3.6), 89 (190), and 0.7 (1.4) μg/L 0.25 h after starting smoking for THC, 11-OH- THC, THCCOOH, CBD, CBN, and THCCOOH-glucuronide, respectively, and 0.5 h for THC-glucuronide.",Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21836075/),[μg] / [l],41,197883,DB00470,Dronabinol
,21836075,observed maximum concentrations (C(max)),"Median whole blood (plasma) observed maximum concentrations (C(max)) were 50 (76), 6.4 (10), 41 (67), 1.3 (2.0), 2.4 (3.6), 89 (190), and 0.7 (1.4) μg/L 0.25 h after starting smoking for THC, 11-OH- THC, THCCOOH, CBD, CBN, and THCCOOH-glucuronide, respectively, and 0.5 h for THC-glucuronide.",Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21836075/),[μg] / [l],1.3,197884,DB00470,Dronabinol
,21836075,observed maximum concentrations (C(max)),"Median whole blood (plasma) observed maximum concentrations (C(max)) were 50 (76), 6.4 (10), 41 (67), 1.3 (2.0), 2.4 (3.6), 89 (190), and 0.7 (1.4) μg/L 0.25 h after starting smoking for THC, 11-OH- THC, THCCOOH, CBD, CBN, and THCCOOH-glucuronide, respectively, and 0.5 h for THC-glucuronide.",Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21836075/),[μg] / [l],2.4,197885,DB00470,Dronabinol
,21836075,observed maximum concentrations (C(max)),"Median whole blood (plasma) observed maximum concentrations (C(max)) were 50 (76), 6.4 (10), 41 (67), 1.3 (2.0), 2.4 (3.6), 89 (190), and 0.7 (1.4) μg/L 0.25 h after starting smoking for THC, 11-OH- THC, THCCOOH, CBD, CBN, and THCCOOH-glucuronide, respectively, and 0.5 h for THC-glucuronide.",Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21836075/),[μg] / [l],89,197886,DB00470,Dronabinol
,21836075,observed maximum concentrations (C(max)),"Median whole blood (plasma) observed maximum concentrations (C(max)) were 50 (76), 6.4 (10), 41 (67), 1.3 (2.0), 2.4 (3.6), 89 (190), and 0.7 (1.4) μg/L 0.25 h after starting smoking for THC, 11-OH- THC, THCCOOH, CBD, CBN, and THCCOOH-glucuronide, respectively, and 0.5 h for THC-glucuronide.",Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21836075/),[μg] / [l],0.7,197887,DB00470,Dronabinol
,2899638,elimination half-life,The elimination half-life for delta 1-tetrahydrocannabinol in blood plasma was calculated to be 4.1 +/- 1.1 days (range 2.9-5.0 days) from the two week plasma level curves.,Prolonged apparent half-life of delta 1-tetrahydrocannabinol in plasma of chronic marijuana users. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2899638/),d,4.1,203172,DB00470,Dronabinol
,2899638,elimination half-life,"Albeit the present results are based upon a small sample, an elimination half-life of delta 1-tetrahydrocannabinol in blood plasma of about 4 days is more in line with apparent half-life excretion of delta 1-tetrahydrocannabinol metabolites in the urine of chronic marijuana smokers.",Prolonged apparent half-life of delta 1-tetrahydrocannabinol in plasma of chronic marijuana users. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2899638/),d,4,203173,DB00470,Dronabinol
,23052407,Cmax,The Cmax for THC in fed versus fasted subjects was higher in 7 subjects (4.80-14.91 ng/ml) and lower in 5 subjects (2.81-3.51 ng/ml) compared with the mean Cmax of 3.98 ng/ml (range 0.97-9.34 ng/ml) observed in the fasted state.,A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23052407/),[ng] / [ml],4.80-14.91,203718,DB00470,Dronabinol
,23052407,Cmax,The Cmax for THC in fed versus fasted subjects was higher in 7 subjects (4.80-14.91 ng/ml) and lower in 5 subjects (2.81-3.51 ng/ml) compared with the mean Cmax of 3.98 ng/ml (range 0.97-9.34 ng/ml) observed in the fasted state.,A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23052407/),[ng] / [ml],2.81-3.51,203719,DB00470,Dronabinol
,23052407,Cmax,The Cmax for THC in fed versus fasted subjects was higher in 7 subjects (4.80-14.91 ng/ml) and lower in 5 subjects (2.81-3.51 ng/ml) compared with the mean Cmax of 3.98 ng/ml (range 0.97-9.34 ng/ml) observed in the fasted state.,A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23052407/),[ng] / [ml],3.98,203720,DB00470,Dronabinol
,22680341,apparent t(1/2),"Oral THC apparent t(1/2) was 72-80 min, t(max) was 39-56 min and C(max) 2.92-4.69 ng ml(-1) .",Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22680341/),min,72-80,207011,DB00470,Dronabinol
,22680341,t(max),"Oral THC apparent t(1/2) was 72-80 min, t(max) was 39-56 min and C(max) 2.92-4.69 ng ml(-1) .",Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22680341/),min,39-56,207012,DB00470,Dronabinol
,22680341,C(max),"Oral THC apparent t(1/2) was 72-80 min, t(max) was 39-56 min and C(max) 2.92-4.69 ng ml(-1) .",Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22680341/),[ng] / [ml],2.92-4.69,207013,DB00470,Dronabinol
,6284775,half life,This revealed a terminal plasma delta 1-THC half life ranging from 34.16 to 59.30 h (mean 46.75 h) after a single dose and THC fat/plasma ratio of 10(3)-10(4):1.,Gas chromatographic and mass spectrometric studies on the metabolism and pharmacokinetics of delta 1-tetrahydrocannabinol in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6284775/),h,34.16 to 59.30,207367,DB00470,Dronabinol
,6284775,half life,This revealed a terminal plasma delta 1-THC half life ranging from 34.16 to 59.30 h (mean 46.75 h) after a single dose and THC fat/plasma ratio of 10(3)-10(4):1.,Gas chromatographic and mass spectrometric studies on the metabolism and pharmacokinetics of delta 1-tetrahydrocannabinol in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6284775/),h,46.75,207368,DB00470,Dronabinol
,6284775,fat/plasma ratio,This revealed a terminal plasma delta 1-THC half life ranging from 34.16 to 59.30 h (mean 46.75 h) after a single dose and THC fat/plasma ratio of 10(3)-10(4):1.,Gas chromatographic and mass spectrometric studies on the metabolism and pharmacokinetics of delta 1-tetrahydrocannabinol in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6284775/),,10,207369,DB00470,Dronabinol
,21078841,Relative bioavailability,"Relative bioavailability was calculated to determine the relative rate and extent of THC absorption; 5 and 15 mg oral THC bioavailability was 92.6% (13.1%) and 98.8% (11.0%) of low- and high-dose Sativex, respectively.",Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21078841/),%,92.6,207952,DB00470,Dronabinol
,21078841,bioavailability,"Relative bioavailability was calculated to determine the relative rate and extent of THC absorption; 5 and 15 mg oral THC bioavailability was 92.6% (13.1%) and 98.8% (11.0%) of low- and high-dose Sativex, respectively.",Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21078841/),%,92.6,207953,DB00470,Dronabinol
,21078841,bioavailability,"Relative bioavailability was calculated to determine the relative rate and extent of THC absorption; 5 and 15 mg oral THC bioavailability was 92.6% (13.1%) and 98.8% (11.0%) of low- and high-dose Sativex, respectively.",Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21078841/),%,98.8,207954,DB00470,Dronabinol
,33386756,bioavailability,Smoking 30 mg of THC decreased the THC bioavailability to 0.68 compared to 10 mg.,Population pharmacokinetic model of blood THC and its metabolites in chronic and occasional cannabis users and relationship with on-site oral fluid testing. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33386756/),,0.68,208572,DB00470,Dronabinol
,25118789,plasma Cmax,"A uniform pharmacokinetic profile was exhibited across all participants (Δ(9)-THC plasma Cmax ± SD was 38 ± 10 ng/mL, Tmax ± SD was 3 ± 1 minutes, AUC₀→infinity ± SD was 607 ± 200 ng·min/mL).","The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25118789/),[ng] / [ml],38,212490,DB00470,Dronabinol
,25118789,Tmax,"A uniform pharmacokinetic profile was exhibited across all participants (Δ(9)-THC plasma Cmax ± SD was 38 ± 10 ng/mL, Tmax ± SD was 3 ± 1 minutes, AUC₀→infinity ± SD was 607 ± 200 ng·min/mL).","The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25118789/),min,3,212491,DB00470,Dronabinol
,25118789,AUC₀→infinity,"A uniform pharmacokinetic profile was exhibited across all participants (Δ(9)-THC plasma Cmax ± SD was 38 ± 10 ng/mL, Tmax ± SD was 3 ± 1 minutes, AUC₀→infinity ± SD was 607 ± 200 ng·min/mL).","The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25118789/),[min·ng] / [ml],607,212492,DB00470,Dronabinol
,25118789,plasma Cmax increase,"Higher plasma Cmax increase per mg Δ(9)-THC administered (12.3 ng/mL/mg THC) and lower interindividual variability of Cmax (25.3%), compared with reported alternative modes of THC delivery, were measured.","The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25118789/),[ng] / [mg·ml],12.3,212493,DB00470,Dronabinol
,25035121,Cmax,"Subjects for whom the Cmax fell within the sampling period (over 2h), Cmax was 1.42-4.57ng/mL and Tmax was 67-92min.",Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: a randomized controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25035121/),[ng] / [ml],1.42-4.57,214542,DB00470,Dronabinol
,25035121,Tmax,"Subjects for whom the Cmax fell within the sampling period (over 2h), Cmax was 1.42-4.57ng/mL and Tmax was 67-92min.",Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: a randomized controlled trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25035121/),min,67-92,214543,DB00470,Dronabinol
,25035121,AUC0-2h,The AUC0-2h (n=11) was 1.67-3.51ng/mL.,Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: a randomized controlled trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25035121/),[ng] / [ml],1.67-3.51,214544,DB00470,Dronabinol
,15063332,recoveries,"The mean recoveries for Delta(9)-tetrahydrocannabinol, 11-nor-Delta(9)-tetrahydrocannabinol-9-carboxylic acid, and 11-hydroxy-Delta(9)-tetrahydrocannabinol were 96, 92, and 85%, respectively.",Liquid chromatographic-mass spectrometric quantitation of Delta9-tetrahydrocannabinol and two metabolites in pharmacokinetic study plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15063332/),%,96,217956,DB00470,Dronabinol
,15063332,recoveries,"The mean recoveries for Delta(9)-tetrahydrocannabinol, 11-nor-Delta(9)-tetrahydrocannabinol-9-carboxylic acid, and 11-hydroxy-Delta(9)-tetrahydrocannabinol were 96, 92, and 85%, respectively.",Liquid chromatographic-mass spectrometric quantitation of Delta9-tetrahydrocannabinol and two metabolites in pharmacokinetic study plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15063332/),%,92,217957,DB00470,Dronabinol
,15063332,recoveries,"The mean recoveries for Delta(9)-tetrahydrocannabinol, 11-nor-Delta(9)-tetrahydrocannabinol-9-carboxylic acid, and 11-hydroxy-Delta(9)-tetrahydrocannabinol were 96, 92, and 85%, respectively.",Liquid chromatographic-mass spectrometric quantitation of Delta9-tetrahydrocannabinol and two metabolites in pharmacokinetic study plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15063332/),%,85,217958,DB00470,Dronabinol
,15063332,limit of detection (LOD),The lower limit of quantification (LLOQ) for all three compounds was 5 ng/ml and the limit of detection (LOD) was 2 ng/ml.,Liquid chromatographic-mass spectrometric quantitation of Delta9-tetrahydrocannabinol and two metabolites in pharmacokinetic study plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15063332/),[ng] / [ml],2,217959,DB00470,Dronabinol
,33952608,Finh,"The inhalation bioavailability (Finh) of THC after inhalation was higher in chronic versus casual cannabis users (Finh = 0.35 and 0.19, respectively).","Development and Verification of a Linked Δ 9-THC/11-OH-THC Physiologically Based Pharmacokinetic Model in Healthy, Nonpregnant Population and Extrapolation to Pregnant Women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33952608/),,0.35,219917,DB00470,Dronabinol
,33952608,Finh,"The inhalation bioavailability (Finh) of THC after inhalation was higher in chronic versus casual cannabis users (Finh = 0.35 and 0.19, respectively).","Development and Verification of a Linked Δ 9-THC/11-OH-THC Physiologically Based Pharmacokinetic Model in Healthy, Nonpregnant Population and Extrapolation to Pregnant Women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33952608/),,0.19,219918,DB00470,Dronabinol
,30852450,run time,The run time was 8.5 min.,Development and validation of an assay to measure cannabidiol and Δ9-tetrahydrocannabinol in human EDTA plasma by UHPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30852450/),min,8.5,221869,DB00470,Dronabinol
,32735381,appx,"A 4 mg/kg dose of total cannabinoids twice daily resulted in appx 10 ng/ml of CBD, 21-32 ng/ml of CBDA, trace amounts of THCA, and unquantifiable amounts of THC in serum at the end of weeks 1 and 2 of treatment.","Serum cannabidiol, tetrahydrocannabinol (THC), and their native acid derivatives after transdermal application of a low-THC Cannabis sativa extract in beagles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32735381/),[ng] / [ml],10,224702,DB00470,Dronabinol
,32735381,appx,"A 4 mg/kg dose of total cannabinoids twice daily resulted in appx 10 ng/ml of CBD, 21-32 ng/ml of CBDA, trace amounts of THCA, and unquantifiable amounts of THC in serum at the end of weeks 1 and 2 of treatment.","Serum cannabidiol, tetrahydrocannabinol (THC), and their native acid derivatives after transdermal application of a low-THC Cannabis sativa extract in beagles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32735381/),[ng] / [ml],21-32,224703,DB00470,Dronabinol
,23601084,terminal half-life,TM38837 showed an estimated terminal half-life of 771 h.,Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23601084/),h,771,226973,DB00470,Dronabinol
,2985774,alpha,Serum concentrations were best described by a sum of two exponentials with alpha and beta half-lives (mean +/- SD) of 0.74 +/- 0.59 and 14.9 +/- 12.5 h.,Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2985774/),h,0.74,226989,DB00470,Dronabinol
,2985774,beta half-lives,Serum concentrations were best described by a sum of two exponentials with alpha and beta half-lives (mean +/- SD) of 0.74 +/- 0.59 and 14.9 +/- 12.5 h.,Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2985774/),h,14.9,226990,DB00470,Dronabinol
,2985774,Apparent bioavailability,"Apparent bioavailability (%F +/- SD) of various formulations of THC were: gelatin capsules, 26 +/- 14; cookie, 89 +/- 16; intramuscularly in Tween-80 and in Emulphor, 39 +/- 13 and 102 +/- 15, respectively.",Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2985774/),,26,226991,DB00470,Dronabinol
,2985774,Apparent bioavailability,"Apparent bioavailability (%F +/- SD) of various formulations of THC were: gelatin capsules, 26 +/- 14; cookie, 89 +/- 16; intramuscularly in Tween-80 and in Emulphor, 39 +/- 13 and 102 +/- 15, respectively.",Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2985774/),,89,226992,DB00470,Dronabinol
,2985774,Apparent bioavailability,"Apparent bioavailability (%F +/- SD) of various formulations of THC were: gelatin capsules, 26 +/- 14; cookie, 89 +/- 16; intramuscularly in Tween-80 and in Emulphor, 39 +/- 13 and 102 +/- 15, respectively.",Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2985774/),,39,226993,DB00470,Dronabinol
,2985774,Apparent bioavailability,"Apparent bioavailability (%F +/- SD) of various formulations of THC were: gelatin capsules, 26 +/- 14; cookie, 89 +/- 16; intramuscularly in Tween-80 and in Emulphor, 39 +/- 13 and 102 +/- 15, respectively.",Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2985774/),,102,226994,DB00470,Dronabinol
,2985774,mean residence times,"Using the method of statistical moments, mean residence times in the body (h +/- SD) were: intravenous, 6.08 +/- 1.60; cookie, 21.92 +/- 3.11; gelatin capsule, 26.80 +/- 23.61; intramuscularly in Emulphor, 10.92 +/- 3.46 (in Tween-80, not calculated).",Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2985774/),h,6.08,226995,DB00470,Dronabinol
,2985774,mean residence times,"Using the method of statistical moments, mean residence times in the body (h +/- SD) were: intravenous, 6.08 +/- 1.60; cookie, 21.92 +/- 3.11; gelatin capsule, 26.80 +/- 23.61; intramuscularly in Emulphor, 10.92 +/- 3.46 (in Tween-80, not calculated).",Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2985774/),h,21.92,226996,DB00470,Dronabinol
,2985774,mean residence times,"Using the method of statistical moments, mean residence times in the body (h +/- SD) were: intravenous, 6.08 +/- 1.60; cookie, 21.92 +/- 3.11; gelatin capsule, 26.80 +/- 23.61; intramuscularly in Emulphor, 10.92 +/- 3.46 (in Tween-80, not calculated).",Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2985774/),h,26.80,226997,DB00470,Dronabinol
,2985774,mean residence times,"Using the method of statistical moments, mean residence times in the body (h +/- SD) were: intravenous, 6.08 +/- 1.60; cookie, 21.92 +/- 3.11; gelatin capsule, 26.80 +/- 23.61; intramuscularly in Emulphor, 10.92 +/- 3.46 (in Tween-80, not calculated).",Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2985774/),h,10.92,226998,DB00470,Dronabinol
,24743363,S/N,The lower limit of quantification was 0.5 ng/mL(S/N=3).,Novel method of determination of D9-tetrahydrocannabinol(THC) in human serum by high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24743363/),,3,228986,DB00470,Dronabinol
,18713514,elimination half-life,"In contrast to the cannabis conditions, the THC concentrations in the placebo phase decreased more slowly (elimination half-life 17.5-43.5 h vs. 1.0-5.9 h) in accordance with a late elimination phase.",Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18713514/),h,17.5-43.5,229165,DB00470,Dronabinol
,18713514,elimination half-life,"In contrast to the cannabis conditions, the THC concentrations in the placebo phase decreased more slowly (elimination half-life 17.5-43.5 h vs. 1.0-5.9 h) in accordance with a late elimination phase.",Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18713514/),h,1.0-5.9,229166,DB00470,Dronabinol
,18713514,elimination half-lives,"The elimination half-lives of 11-hydroxy-THC and 11-nor-9-carboxy-THC in th cannabis conditions (medians 3.1 h and 6.2 h, respectively) were longer than those of THC, which was different in the placebo phase (medians 7.2 h and 13.0 h, respectively).",Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18713514/),h,3.1,229167,DB00470,Dronabinol
,18713514,elimination half-lives,"The elimination half-lives of 11-hydroxy-THC and 11-nor-9-carboxy-THC in th cannabis conditions (medians 3.1 h and 6.2 h, respectively) were longer than those of THC, which was different in the placebo phase (medians 7.2 h and 13.0 h, respectively).",Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18713514/),h,6.2,229168,DB00470,Dronabinol
,18713514,elimination half-lives,"The elimination half-lives of 11-hydroxy-THC and 11-nor-9-carboxy-THC in th cannabis conditions (medians 3.1 h and 6.2 h, respectively) were longer than those of THC, which was different in the placebo phase (medians 7.2 h and 13.0 h, respectively).",Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18713514/),h,7.2,229169,DB00470,Dronabinol
,18713514,elimination half-lives,"The elimination half-lives of 11-hydroxy-THC and 11-nor-9-carboxy-THC in th cannabis conditions (medians 3.1 h and 6.2 h, respectively) were longer than those of THC, which was different in the placebo phase (medians 7.2 h and 13.0 h, respectively).",Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18713514/),h,13.0,229170,DB00470,Dronabinol
,21244195,C(max),"After nasal administration, the THC nasal solution afforded a C(max) value of 20 ± 3 ng/mL at 20 minutes.",Bioavailability of Δ⁹-tetrahydrocannabinol following intranasal administration of a mucoadhesive gel spray delivery system in conscious rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21244195/),[ng] / [ml],20,229704,DB00470,Dronabinol
,21244195,C(max),"Interestingly, the THC loaded in chitosan gel formulation followed almost the same profile at early time points and subsequently afforded a higher C(max) value of 31 ± 4 ng/mL (T(max) = 45 minutes).",Bioavailability of Δ⁹-tetrahydrocannabinol following intranasal administration of a mucoadhesive gel spray delivery system in conscious rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21244195/),[ng] / [ml],31,229705,DB00470,Dronabinol
,21244195,T(max),"Interestingly, the THC loaded in chitosan gel formulation followed almost the same profile at early time points and subsequently afforded a higher C(max) value of 31 ± 4 ng/mL (T(max) = 45 minutes).",Bioavailability of Δ⁹-tetrahydrocannabinol following intranasal administration of a mucoadhesive gel spray delivery system in conscious rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21244195/),min,45,229706,DB00470,Dronabinol
,21244195,Absolute bioavailability,"Absolute bioavailability values were 13.3 ± 7.8% and 15.4 ± 6.5% for the THC nasal solution and gel formulations, respectively.",Bioavailability of Δ⁹-tetrahydrocannabinol following intranasal administration of a mucoadhesive gel spray delivery system in conscious rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21244195/),%,13.3,229707,DB00470,Dronabinol
,21244195,Absolute bioavailability,"Absolute bioavailability values were 13.3 ± 7.8% and 15.4 ± 6.5% for the THC nasal solution and gel formulations, respectively.",Bioavailability of Δ⁹-tetrahydrocannabinol following intranasal administration of a mucoadhesive gel spray delivery system in conscious rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21244195/),%,15.4,229708,DB00470,Dronabinol
,1666913,bioavailability,Subsequent studies in the conscious dog using the hemisuccinate in Witepsol H15 showed 67% bioavailability of delta 9-THC with a linear response in the dose range equivalent to 5-20 mg of delta 9-THC.,Rectal bioavailability of delta-9-tetrahydrocannabinol from various esters. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1666913/),%,67,231470,DB00470,Dronabinol
,20450927,Cmax,"The median pharmacokinetic parameters generated by the model were Cmax=175ng/mL, Tmax=14min, and AUC0-8h=8150ng×min/mL for the 69.4mg THC dose.",Disposition of smoked cannabis with high Δ(9)-tetrahydrocannabinol content: a kinetic model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20450927/),[ng] / [ml],175,236838,DB00470,Dronabinol
,20450927,Tmax,"The median pharmacokinetic parameters generated by the model were Cmax=175ng/mL, Tmax=14min, and AUC0-8h=8150ng×min/mL for the 69.4mg THC dose.",Disposition of smoked cannabis with high Δ(9)-tetrahydrocannabinol content: a kinetic model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20450927/),min,14,236839,DB00470,Dronabinol
,20450927,AUC0-8h,"The median pharmacokinetic parameters generated by the model were Cmax=175ng/mL, Tmax=14min, and AUC0-8h=8150ng×min/mL for the 69.4mg THC dose.",Disposition of smoked cannabis with high Δ(9)-tetrahydrocannabinol content: a kinetic model. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20450927/),[min·ng] / [ml],8150,236840,DB00470,Dronabinol
,20450927,Cmax/Dose,Median model results show an almost linear dose response relation for Cmax/Dose=2.8×10(-6)/mL and AUC0-8h/Dose=136×10(-6)min/mL.,Disposition of smoked cannabis with high Δ(9)-tetrahydrocannabinol content: a kinetic model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20450927/),,2.8×,236841,DB00470,Dronabinol
,20450927,AUC0-8h/Dose,Median model results show an almost linear dose response relation for Cmax/Dose=2.8×10(-6)/mL and AUC0-8h/Dose=136×10(-6)min/mL.,Disposition of smoked cannabis with high Δ(9)-tetrahydrocannabinol content: a kinetic model. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20450927/),[min] / [ml],136×10(-6),236842,DB00470,Dronabinol
,20450927,Cmax/Dose,"However, for increasing dose level, there was a clear decreasing trend: Cmax/Dose=3.4, 2.6 and 2.5×10(-6)/mL and AUC0-8h/Dose=157, 133 and 117×10(-6)min/mL for the 29.3, 49.1 and 69.4mg dose, respectively.",Disposition of smoked cannabis with high Δ(9)-tetrahydrocannabinol content: a kinetic model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20450927/),,3.4,236843,DB00470,Dronabinol
,20450927,Cmax/Dose,"However, for increasing dose level, there was a clear decreasing trend: Cmax/Dose=3.4, 2.6 and 2.5×10(-6)/mL and AUC0-8h/Dose=157, 133 and 117×10(-6)min/mL for the 29.3, 49.1 and 69.4mg dose, respectively.",Disposition of smoked cannabis with high Δ(9)-tetrahydrocannabinol content: a kinetic model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20450927/),,2.6,236844,DB00470,Dronabinol
,20450927,Cmax/Dose,"However, for increasing dose level, there was a clear decreasing trend: Cmax/Dose=3.4, 2.6 and 2.5×10(-6)/mL and AUC0-8h/Dose=157, 133 and 117×10(-6)min/mL for the 29.3, 49.1 and 69.4mg dose, respectively.",Disposition of smoked cannabis with high Δ(9)-tetrahydrocannabinol content: a kinetic model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20450927/),,2.5×10(-6),236845,DB00470,Dronabinol
,20450927,AUC0-8h/Dose,"However, for increasing dose level, there was a clear decreasing trend: Cmax/Dose=3.4, 2.6 and 2.5×10(-6)/mL and AUC0-8h/Dose=157, 133 and 117×10(-6)min/mL for the 29.3, 49.1 and 69.4mg dose, respectively.",Disposition of smoked cannabis with high Δ(9)-tetrahydrocannabinol content: a kinetic model. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20450927/),[min] / [ml],157,236846,DB00470,Dronabinol
,20450927,AUC0-8h/Dose,"However, for increasing dose level, there was a clear decreasing trend: Cmax/Dose=3.4, 2.6 and 2.5×10(-6)/mL and AUC0-8h/Dose=157, 133 and 117×10(-6)min/mL for the 29.3, 49.1 and 69.4mg dose, respectively.",Disposition of smoked cannabis with high Δ(9)-tetrahydrocannabinol content: a kinetic model. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20450927/),[min] / [ml],133,236847,DB00470,Dronabinol
,20450927,AUC0-8h/Dose,"However, for increasing dose level, there was a clear decreasing trend: Cmax/Dose=3.4, 2.6 and 2.5×10(-6)/mL and AUC0-8h/Dose=157, 133 and 117×10(-6)min/mL for the 29.3, 49.1 and 69.4mg dose, respectively.",Disposition of smoked cannabis with high Δ(9)-tetrahydrocannabinol content: a kinetic model. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20450927/),[min] / [ml],117×10(-6),236848,DB00470,Dronabinol
,20450927,AUC0-8h/Dose,"However, for increasing dose level, there was a clear decreasing trend: Cmax/Dose=3.4, 2.6 and 2.5×10(-6)/mL and AUC0-8h/Dose=157, 133 and 117×10(-6)min/mL for the 29.3, 49.1 and 69.4mg dose, respectively.",Disposition of smoked cannabis with high Δ(9)-tetrahydrocannabinol content: a kinetic model. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20450927/),,49,236849,DB00470,Dronabinol
,20450927,apparent terminal half life,"Within the restriction of 8h of observation, the apparent terminal half life of THC was 150min.",Disposition of smoked cannabis with high Δ(9)-tetrahydrocannabinol content: a kinetic model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20450927/),min,150,236850,DB00470,Dronabinol
,17014999,T(max),"WIN55,212-2 was absorbed more rapidly (T(max)=0.2-0.3h) than Delta(9)-THC (T(max)=1.5-1.6h) and to a higher extent than Delta(9)-THC.","Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17014999/),h,0.2-0.3,241047,DB00470,Dronabinol
,17014999,T(max),"WIN55,212-2 was absorbed more rapidly (T(max)=0.2-0.3h) than Delta(9)-THC (T(max)=1.5-1.6h) and to a higher extent than Delta(9)-THC.","Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17014999/),h,1.5-1.6,241048,DB00470,Dronabinol
,17014999,absolute bioavailability (F(abs)),"Furthermore, it had no significant effect on the absolute bioavailability (F(abs)): F(abs)=6.4+/-2.4% and 9.1+/-3.0% for Delta(9)-THC in propylene glycol, with and without ethanol, respectively.","Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17014999/),%,6.4,241049,DB00470,Dronabinol
,17014999,F(abs),"Furthermore, it had no significant effect on the absolute bioavailability (F(abs)): F(abs)=6.4+/-2.4% and 9.1+/-3.0% for Delta(9)-THC in propylene glycol, with and without ethanol, respectively.","Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17014999/),%,6.4,241050,DB00470,Dronabinol
,17014999,F(abs),"Furthermore, it had no significant effect on the absolute bioavailability (F(abs)): F(abs)=6.4+/-2.4% and 9.1+/-3.0% for Delta(9)-THC in propylene glycol, with and without ethanol, respectively.","Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17014999/),%,9.1,241051,DB00470,Dronabinol
,17014999,F(abs),"For WIN55,212-2, F(abs)=49.9+/-6.9% (propylene glycol alone) and 56.6+/-14.1% (propylene glycol with 10% ethanol).","Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17014999/),%,49.9,241052,DB00470,Dronabinol
,17014999,F(abs),"For WIN55,212-2, F(abs)=49.9+/-6.9% (propylene glycol alone) and 56.6+/-14.1% (propylene glycol with 10% ethanol).","Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17014999/),%,56.6,241053,DB00470,Dronabinol
,891094,plasma half-life,"Antipyrine plasma half-life increased during THC in 5 of 6 subjects--mean, 7.9 hr +/- 3.3 (SD) to 9.6 +/- 3.8.","Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/891094/),h,7.9,246096,DB00470,Dronabinol
,891094,plasma half-life,"Antipyrine plasma half-life increased during THC in 5 of 6 subjects--mean, 7.9 hr +/- 3.3 (SD) to 9.6 +/- 3.8.","Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/891094/),h,9.6,246097,DB00470,Dronabinol
,891094,half-life,"Pentobarbital half-life increased in 7 of 8 subjects--mean, 16.9 hr +/- 2.0 to 20.8 +/- 4.2.","Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/891094/),h,16.9,246098,DB00470,Dronabinol
,891094,half-life,"Pentobarbital half-life increased in 7 of 8 subjects--mean, 16.9 hr +/- 2.0 to 20.8 +/- 4.2.","Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/891094/),h,20.8,246099,DB00470,Dronabinol
,891094,Blood ethanol disappearance rate,Blood ethanol disappearance rate decreased in 7 of 8 subjects from a mean of 0.26 mg/100 ml/min +/- 0.05 to 0.23 +/- 0.07.,"Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. ",km-Q51,[Article Link](https://pubmed.ncbi.nlm.nih.gov/891094/),[mg] / [100·min·ml],0.26,246100,DB00470,Dronabinol
,891094,Blood ethanol disappearance rate,Blood ethanol disappearance rate decreased in 7 of 8 subjects from a mean of 0.26 mg/100 ml/min +/- 0.05 to 0.23 +/- 0.07.,"Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. ",km-Q51,[Article Link](https://pubmed.ncbi.nlm.nih.gov/891094/),[mg] / [100·min·ml],0.23,246101,DB00470,Dronabinol
<,23179176,Cmax,"The mean Cmax values (<12 ng/mL) recorded in this study were well below those reported in patients who smoked/inhaled cannabis, which is reassuring since elevated Cmax values are linked to significant psychoactivity.",A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179176/),[ng] / [ml],12,246727,DB00470,Dronabinol
,15067692,steady-state level,"On application of the TTS patch, the plasma concentration of Delta(8)-THC reached a mean steady-state level of 4.4 ng/mL within 1.4 h and was maintained for at least 48 h.",In vitro/in vivo correlation studies for transdermal delta 8-THC development. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15067692/),[ng] / [ml],4.4,253027,DB00470,Dronabinol
,20465868,maximum concentrations,"The oral fluid analyses exhibited no significant differences between 12 occasional users and 12 chronic users smoking a standardized cannabis joint, except for the maximum concentrations in the first samples (occasional users, 397- 6438 ng/g; chronic users 387-71,747 ng/g).",Pharmacokinetic properties of delta9-tetrahydrocannabinol in oral fluid of occasional and chronic users. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20465868/),[ng] / [g],397- 6438,261782,DB00470,Dronabinol
,20465868,maximum concentrations,"The oral fluid analyses exhibited no significant differences between 12 occasional users and 12 chronic users smoking a standardized cannabis joint, except for the maximum concentrations in the first samples (occasional users, 397- 6438 ng/g; chronic users 387-71,747 ng/g).",Pharmacokinetic properties of delta9-tetrahydrocannabinol in oral fluid of occasional and chronic users. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20465868/),[ng] / [g],"387-71,747",261783,DB00470,Dronabinol
,20465868,elimination half-life,The elimination half-life in both groups was 1.6 +/- 0.4 h.,Pharmacokinetic properties of delta9-tetrahydrocannabinol in oral fluid of occasional and chronic users. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20465868/),h,1.6,261784,DB00470,Dronabinol
,20465868,oral fluid-to-serum ratios,The oral fluid-to-serum ratios were 0.3 to 425 (median 16.5) with no difference between chronic and occasional users.,Pharmacokinetic properties of delta9-tetrahydrocannabinol in oral fluid of occasional and chronic users. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20465868/),,16.5,261785,DB00470,Dronabinol
,8897084,peak plasma levels,"After oral doses of 10-15 mg THC, peak plasma levels from 2.1 to 16.9 ng/ml THC and 74.5 to 244.0 ng/ml 11-nor-9-carboxy-delta 9-tetrahydrocannabinol (THC-COOH, major THC metabolite) were measured by GC/MS within 1-8 h and 2-8 h, respectively.",The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897084/),[ng] / [ml],2.1 to 16.9,261953,DB00470,Dronabinol
,8897084,peak plasma levels,"After oral doses of 10-15 mg THC, peak plasma levels from 2.1 to 16.9 ng/ml THC and 74.5 to 244.0 ng/ml 11-nor-9-carboxy-delta 9-tetrahydrocannabinol (THC-COOH, major THC metabolite) were measured by GC/MS within 1-8 h and 2-8 h, respectively.",The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897084/),[ng] / [ml],74.5 to 244.0,261954,DB00470,Dronabinol
,8897084,peak plasma levels,"After rectal doses of 2.5-5 mg THC, peak plasma levels from 1.1 to 4.1 ng/ml THC and 6.1 to 42.0 ng/ml THC-COOH were measured within 2-8 h and 1-8 h, respectively.",The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897084/),[ng] / [ml],1.1 to 4.1,261955,DB00470,Dronabinol
,8897084,peak plasma levels,"After rectal doses of 2.5-5 mg THC, peak plasma levels from 1.1 to 4.1 ng/ml THC and 6.1 to 42.0 ng/ml THC-COOH were measured within 2-8 h and 1-8 h, respectively.",The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897084/),[ng] / [ml],6.1 to 42.0,261956,DB00470,Dronabinol
,8897084,bioavailability,"The bioavailability resulting from the oral formulation was 45-53% relative to the rectal route of administration, due to a lower absorption and higher first-pass metabolism.",The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897084/),%,45-53,261957,DB00470,Dronabinol
,15067694,bioavailability,The bioavailability of the pulmonal THC was 28.7 +/- 8.2% (mean +/- SEM).,Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15067694/),%,28.7,265130,DB00470,Dronabinol
,17529896,recovery,"The amount of conjugated THCCOOH ranged from 149.3 to 559.8 (mean +/- SD, 342.8 +/- 117.3) microg, representing a recovery of 3% to 11% of the administered dose.",The urinary disposition of intravenously administered 11-nor-9-carboxy-delta-9-tetrahydrocannabinol in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529896/),%,3,268102,DB00470,Dronabinol
,17529896,recovery,"The amount of conjugated THCCOOH ranged from 149.3 to 559.8 (mean +/- SD, 342.8 +/- 117.3) microg, representing a recovery of 3% to 11% of the administered dose.",The urinary disposition of intravenously administered 11-nor-9-carboxy-delta-9-tetrahydrocannabinol in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529896/),%,11,268103,DB00470,Dronabinol
,17529896,Urinary elimination half-life,"Urinary elimination half-life of unconjugated and conjugated THCCOOH ranged from 9.0 to 27.4 (mean +/- SD, 17.3 +/- 5.3) hours and from 10.7 to 27.6 (mean +/- SD, 16.0 +/- 5.0) hours, respectively.",The urinary disposition of intravenously administered 11-nor-9-carboxy-delta-9-tetrahydrocannabinol in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529896/),h,9.0 to 27.4,268104,DB00470,Dronabinol
,17529896,Urinary elimination half-life,"Urinary elimination half-life of unconjugated and conjugated THCCOOH ranged from 9.0 to 27.4 (mean +/- SD, 17.3 +/- 5.3) hours and from 10.7 to 27.6 (mean +/- SD, 16.0 +/- 5.0) hours, respectively.",The urinary disposition of intravenously administered 11-nor-9-carboxy-delta-9-tetrahydrocannabinol in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529896/),h,17,268105,DB00470,Dronabinol
,17529896,Urinary elimination half-life,"Urinary elimination half-life of unconjugated and conjugated THCCOOH ranged from 9.0 to 27.4 (mean +/- SD, 17.3 +/- 5.3) hours and from 10.7 to 27.6 (mean +/- SD, 16.0 +/- 5.0) hours, respectively.",The urinary disposition of intravenously administered 11-nor-9-carboxy-delta-9-tetrahydrocannabinol in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529896/),h,10.7 to 27.6,268106,DB00470,Dronabinol
,17529896,Urinary elimination half-life,"Urinary elimination half-life of unconjugated and conjugated THCCOOH ranged from 9.0 to 27.4 (mean +/- SD, 17.3 +/- 5.3) hours and from 10.7 to 27.6 (mean +/- SD, 16.0 +/- 5.0) hours, respectively.",The urinary disposition of intravenously administered 11-nor-9-carboxy-delta-9-tetrahydrocannabinol in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529896/),h,16.0,268107,DB00470,Dronabinol
